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Ischemic Stroke Induces Delayed
Mesencephalic Astrocyte-Derived
Neurotrophic Factor (MANF) Protein
Expression in Brain Inflammatory Cells
J. E. Anttila1, O. S. Mattila2, T. Kuan-Yin1,3,
M. Lindahl1, P. J. Lindsberg2, and M. Airavaara1
1Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki,
Finland
2Neurology, Clinical Neurosciences, University of Helsinki and
Helsinki University Hospital, Helsinki, Finland
3Department of Neurological Surgery, Tri-Service General
Hospital and National Defense Medical Center, Taipei, Taiwan
Mesencephalic astrocyte-derived neurotrophic factor
(MANF) is an endoplasmic reticulum (ER)-resident protein
important for ER homeostasis and protects neurons from
various injuries. MANF is neuroprotective in ischemic injury,
and post-stroke MANF treatment promotes recovery. In the
normal brain MANF protein expression is neuronal, but
expression after ischemia is poorly characterized. Utilizing
immunohistochemistry, we studied how endogenous cerebral
MANF expression evolves after focal cerebral ischemia in rats
(post-stroke day (psd) 2, 7, 14, 28, 56, and 112), mice (psd14),
and humans (psd1–2). Cortical infarct was induced with tran-
sient (90 min) distal middle cerebral artery occlusion (dMCAo)
in rats and permanent dMCAo in mice. Gene-modified Nes-
tinCre/þ:: Manffl/fl mice were used to investigate post-stroke
MANF expression after neuronal and astroglial MANF dele-
tion. Specificity of the anti-MANF antibody was confirmed
with pre-adsorption controls and MANF knockout tissue. In
comparison to the contralateral hemisphere, MANF expression
was markedly decreased in the infarct core at psd2 in rats and
humans. However, MANF was strongly upregulated in the
infarct core at psd7 in rats simultaneously with the phagocytic
marker CD68. MANF was also upregulated in areas of second-
ary damage, i.e. the striatum and thalamus, starting from psd14,
coinciding again with CD68 upregulation. Colocalization of
MANF and CD68 was verified using confocal microscopy.
In the NestinCre/þ:: Manffl/fl mice MANF expression was
also induced in the infarct core, peri-infarct region, and the
ipsilateral striatum and thalamus at psd14, verifying that the
post-ischemic MANF upregulation was not neuronal nor astro-
glial. In conclusion, we are the first to show how endogenous
MANF expression is temporally altered after cerebral ischemia
and demonstrate that MANF is evidently expressed in phago-
cytic microglia/macrophages at later time points. We also pro-
vide the first human data on post-stroke MANF expression.
Our findings provide important insight into how endogenous
MANF may contribute to post-stroke recovery and the regen-
erative role of phagocytes, supporting further investigation into
MANF-based therapeutic applications.
Development and Characterization of
hiPSC Cortical Neurons and their
Application to Drug Evaluation in CNS
Disease Models
K. Autar1, X. Guo1, A. Goswami1, M. Jackson2,
J. W. Rumsey2, C. Long2, and J. J. Hickman1,2
1Nanoscience Technology Center, University of Central Florida,
Orlando, FL, USA
2Hesperos Inc., Orlando, FL, USA
The differentiation of functional cortical neurons from human
induced pluripotent stem cells in vitro easily lends itself to a
serum-free, drug-delivery platform advantageous for testing
novel chemicals for safety and efficacy in disease treatment.
Initially, cortical neuron cultures were characterized morpho-
logically by phase microscopy and immunocytochemistry and
functionally by patch-clamp electrophysiology. Specifically,
the expression of neuronal markers and neuronal activity
increased throughout maturation. On day 0 of maturation,
50% of the culture expressed layer V cortical neuron marker
ctip2 and neuronal marker beta-III tubulin and displayed spon-
taneous and repetitive firing through whole-cell patch clamp.
By day 28 of maturation, 90% of the culture expressed the
aforementioned markers and displayed electrical activity. Sub-
sequently, neurons were cultured on multi-electrode arrays
(MEAs) to determine the effects of chemicals on neural circuit
physiology for modeling brain disease phenotypes. In this sys-
tem, we tested GABAA receptor antagonists and agonists as
chemical convulsants or anti-convulsants, respectively.
GABAA receptor antagonist administration enhanced
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spontaneous activity mimicking an epileptic phenotype, while
GABAA receptor agonist administration quieted spontaneous
activity. The versatility of this model lies in its ability to present
an array of brain diseases characterized by functional brain
deficits. Chemicals affecting receptor binding can be added
to manipulate neuronal activity. This serum-free, hiPSC corti-
cal neuron model establishes a platform for the evaluation of
neuron activity as well as a platform for drug testing in vitro.
Progerin Induced Aging of the Rat
Nigrostriatal System
T. J. Collier1,2, F. P. Manfredsson1,2, B. F. Daley1,
and I. M. Sandoval1,2
1Department of Translational Science & Molecular Medicine,
College of Human Medicine, Michigan State University, Grand
Rapids, MI, USA
2Hauenstein Neuroscience Center, Mercy Health Saint Mary’s,
Grand Rapids, MI, USA
Aging is the greatest risk factor for development of Parkin-
son’s disease (PD). Yet, interrogating the biological intersec-
tion between aging and PD in rodents is challenging as these
animals do not exhibit PD-like neurodegeneration even at
advanced ages. It has been speculated that this may be attri-
butable, in part, to their limited lifespan. We asked the ques-
tion “if aging is accelerated in the nigrostriatal system of
young adult rats, will PD-like degeneration of this system
ensue?” To test this, we ectopically over-expressed progerin
in the midbrain of rats using recombinant adeno-associated
viral vectors (rAAV). Progerin is the protein responsible for
the human genetic premature aging disorder Hutchinson–Gil-
ford syndrome and is a mutant version of the filament protein
Lamin A, a major component of the nuclear lamina. Expres-
sion of progerin induces many phenotypes, including abnor-
mal nuclear shape, loss of heterochromatin, and increased
DNA damage, leading to cellular senescence. In a proof-of-
concept experiment we delivered rAAV-progerin or rAAV-
mCherry (control vector) into the substantia nigra of young
adult (3-month-old) rats. Ten weeks later, tissue was collected
and processed for histological analysis. Immunostaining for
progerin confirmed successful viral transduction and proper
nuclear localization. Immunostaining for tyrosine hydroxy-
lase revealed severe loss of midbrain dopamine neurons.
Ongoing studies are aimed at further characterizing this
model, including a progerin dose response, the analysis of
nuclear morphology, alterations in epigenetic markers, quan-
tification of DNA damage, the temporal course of neural
degeneration, and selective vulnerability of neuronal popula-
tions. Our findings indicate that progerin overexpression can
produce local acceleration of the aging process leading to
neurodegeneration in young rats. Progerin expression may
serve as a useful tool to manipulate aging in models of
aging-related neurodegeneration in short-lived species.
Support: Gibby and Friends vs Parky fund at Michigan
State University.
Addressing Concerns of Neurological
Chimeras in Human–Animal Blastocyst
Complementation
A. T. Crane1, J. P. Voth1, F. X. Shen2,3,
and W. C. Low1,3
1Department of Neurosurgery, University of Minnesota,
Minneapolis, MN, USA
2University of Minnesota Law School, Minneapolis, MN, USA
3Graduate Program in Neuroscience, University of Minnesota,
Minneapolis, MN, USA
Blastocyst complementation is an emerging methodology in
which human stem cells are transferred into genetically engi-
neered preimplantation animal embryos. The microinjected
embryos are transferred to a surrogate eventually giving rise
to fully developed human tissues and organs within the animal
host for use in regenerative medicine. The ethical, legal, and
social implications surrounding this method have caused the
National Institutes of Health to issue a moratorium on funding
that involves the injection of human pluripotent stem cells into
preimplantation animal embryos. A noted concern over blas-
tocyst complementation is the “creation of human–animal
beings with partly or substantially human brains” and whether
such chimeras possess “humanized” characteristics. To
address this concern, we performed a review of the neural
transplantation literature in which human cells have been
transplanted into a nonhuman animal. Our aim was to deter-
mine how the integration of human cells into the nonhuman
neural circuitry has altered the cytoarchitecture and/or beha-
vior of the host. Despite reports of widespread integration of
human cell transplants, our review of 150 transplantation stud-
ies found no evidence suggestive of humanization of the ani-
mal host. We conclude that, at present, concerns over
humanization should not prevent research on blastocyst com-
plementation to continue. Caveats of our study include the
species and age of the animal in which human cells were
transplanted. Of note for regenerative cell therapies for neu-
rological disorders, neural precursors derived from the fetal
brain are the most suitable for transplantation, therefore
addressing the concerns of live-born chimeras that may
express human behaviors. We suggest proceeding in a con-
trolled and transparent manner, and have included recommen-
dations for future research with careful consideration for how
human cells may contribute to the animal host nervous system.
Serotonergic Hyperinnervation in Non-
Motor Circuits in the Parkinsonian Rat
M. Davidsson1, R. C. Sellnow1, R. Yonkers1,
A. M. Zador2, and F. P. Manfredsson1
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It is becoming increasingly clear that non-motor symptoms
(NMS) in Parkinson’s disease (PD) comprise a significant por-
tion of debilitating features of the disease, and such symptoms
are often more debilitating than the motor symptoms them-
selves. Despite its initial effectiveness, chronic L-DOPA
administration leads to motor side effects such as L-DOPA-
induced dyskinesias (LID) in up to 90% of patients and NMS in
as many as 60% of patients. Reports have revealed extensive
modifications to serotonergic (5-HT) innervation of the stria-
tum as dopamine (DA) cells are lost, and that these 5-HT
terminals are crucial in the formation of LID. However, it is
unclear what changes occur in other areas of the brain. To
address this we utilized an AAV reporter virus to label the
dorsal raphe (DR) 5-HT innervation in the hemiparkinsonian
rat. 5-HT innervation from the DR was dramatically enhanced
in areas such as the amygdala and prefrontal cortex, suggesting
that changes in 5-HT circuitry may be responsible for NMS. In
order to better understand the role of this circuitry in NMS we
generated a projection-specific viral vector approach whereby
specific DR 5-HT terminals are targeted using novel AAV
vectors with retrograde transport capacity, and paired with viral
vectors expressing regulatory elements specifically in the 5-HT
soma. However, in order to achieve single circuitry precision
we need to better understand individual projections. Thus, in
ongoing experimentation we are using Multiplexed Analysis of
Projections by Sequencing (MAPseq) in combination with
AAV, DNA barcoding, and Next Generation Sequencing in
order to fully map each individual 5-HT projection from the
dorsal raphe. This approach will systematically determine how
neuroadaptation in 5-HT innervation and function modulate
DA neurotransmission in the parkinsonian brain, facilitating
therapeutic targeting of such maladaptive changes to optimize
NMF treatment and therefore quality of life for PD patients.
Evaluation of DNA-Binding Domains to
Selectively Reduce the Expression of
Mutant Huntingtin in Patient-Derived Cells
and Transgenic Mice
P. Deng1,2,3, J. Halmai1,2, S. del Campo1,2,
D. Cameron1,2, J. Waldo1,2, I. Sandoval4,
F. Manfredsson4, J. Nolta1, D. Segal3, and K. Fink1,2
1Stem Cell Program and Institute for Regenerative Cures,
University of California Davis Health Systems, Sacramento, CA,
USA
2Department of Neurology, University of California Davis Health
Systems, Sacramento, CA, USA
3Genome Center, MIND Institute, and Biochemistry and
Molecular Medicine, University of California, Davis, CA, USA
4Department of Translational Science and Molecular Medicine,
College of Human Medicine, Michigan State University, Grand
Rapids, MI, United States; Mercy Health Saint Mary’s, Grand
Rapids, MI, USA
Huntington’s disease (HD) is an autosomal dominant neuro-
degenerative disorder characterized by the presence of a
misfolded mutant Huntingtin (muHTT) protein. Reduction
of muHTT is an attractive therapeutic approach; however,
one must take into consideration the role of the normal, non-
expanded version of Huntingtin. An ideal therapeutic
approach would be able to selectively silence only the
expanded allele, affect a large population of striatal neurons,
and have a durable effect. We have previously shown allele-
specific silencing of the muHTT transcript in patient-derived
fibroblasts via transcription activator-like effectors (TALE)
by targeting a single nucleotide polymorphisms (SNP) that is
highly associated with the mutant allele. In this study we
examine the use of an adeno-associated virus (AAV) as
putative delivery vehicle for our therapeutic TALE trans-
gene. AAV9-TALE was directly injected into the striatum
of YAC128 at an early stage (9 months of age) of HD-like
symptoms. Mice were then tested on a motor coordination
task to evaluate functional recovery every 2 weeks until they
were 12 months of age, at which point brains were analyzed
via immunohistochemistry (IHC) for expression of the
TALE and for molecular assessment for reduction of
muHTT at the RNA and protein level. Presently, our data
demonstrate a functional sparing, attenuation of striatal atro-
phy, and reduction of muHTT following injection of AAV9-
TALE into the YAC128 transgenic HD mouse. Additionally,
we have expanded this work to include a novel Cas9 variant
(xCas9.3.7) that has broad PAM specificity. This novel con-
struct was cloned into our iCas9 backbone to allow for the
evaluation of various effector domains in both an indepen-
dent and in combinational fashion. dxiCas9 was fused with
either KRAB, DMNT3a, or both and guide RNAs were
designed for previously identified SNPs in our patient cell
lines (Fibroblasts GM02151, GM04281b, GM04287 and
iPSC NN003930 and NN0000033). Following nucleofection
of both guide RNA and dxiCas9 constructs, significant
reduction of huntingtin was observed. The ability of TALE
or dxiCas9 to selectively reduce expression of mutant hun-
tingtin carries significant therapeutic value.
Temporal Activation of Paternal Ube3a in
Angelman Syndrome Reporter Mouse
Following Transplantation of Zinc Finger
Secreted Mesenchymal Stem Cells
P. Deng1,2, U. Beitnere2, R. D. Lee4, B. Pyles2,
H. O’Geen2, J. A. N. M. Halmai1, J. A. Nolta1,
D. J. Segal2, and K. D. Fink1,3
1Stem Cell Program and Institute for Regenerative Cures,
University of California, Davis Health Systems, Sacramento, CA,
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2Genome Center, MIND Institute, and Biochemistry and
Molecular Medicine, University of California, Davis, CA, USA
3Department of Neurology, University of California, Davis Heath
Systems, Sacramento, CA, USA
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4School of Medicine, University of California, Davis Health
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Angelman syndrome (AS) is a genetically inherited neuro-
developmental disorder characterized by impaired cognitive
development, lack of speech, seizures, and motor ataxia. The
genetic cause for AS is usually due to a de novo deletion of
the maternal ubiquitin protein ligase E3a (UBE3a) gene in
the chromosome 15q11-q13 region. Additionally, brain-
specific postnatal imprinting of the intact paternal UBE3a
gene results in complete loss of UBE3a in mature neurons
due to the presence of a long antisense transcript driven by
the neighboring small nuclear ribonucleoprotein polypeptide
N (SNURF/SNRPN) promoter. Our group has previously
shown re-activation of the paternally silent Ube3a gene in
the brains of the E6-AP adult AS mouse following intraper-
itoneal (i.p.) injection of a Kruppel-associated box (KRAB)-
fused Zinc Finger (referred to as S1 K) protein targeted
toward the Snurf/Snrpn promoter—effectively silencing
expression of the antisense transcript. As an alternative
delivery method, we have engineered activating transcrip-
tion factor (ATF)-secreting bone-derived mesenchymal stem
cells following lentiviral reprogramming.
Presently, we have engineered mouse bone marrow-
derived mesenchymal stem cells (BM-MSCs) to secrete S1
K as confirmed by uptake into Neuro2a cells with MSC-S1
K conditioned media via fluorescent microscopy. Incubation
of MSC-S1 K conditioned media with E15.5 E6-AP: YFP
AS mouse primary neurons demonstrated significant re-
activation of YFP fused Ube3a as compared with a scramble
zinc finger MSC (MSC-SR6) and non-transduced MSC
(MSC-NT) 48-hrs post treatment. We then bilaterally trans-
planted 250,000 MSCs from each treatment type into their
respective treatment arms (MSC-S1 K, MSC-SR6, MSC-
NT) into 8-week old E6-AP: YFP mice. We observed
significant re-activation of silent Ube3a via immunohisto-
chemistry (IHC) and western blotting for YFP expression in
the hippocampus, cerebellum, and cortex as compared to
MSC-SR6 and MSC-NT treatment groups 3 and 6 weeks
post-transplantation. Currently, we report the first-in-its-
kind use of MSCs as a delivery platform for genetic modi-
fiers in disease.
Conditioned Medium Derived from
Endothelial Progenitor Cells Exerts
Neuroprotection on Cultured Cortical and
Midbrain Neuronal Stem Cells
S. Di Santo, S. Seiler, D. Skrzypczak, T. Bieri,
and H. R. Widmer
Department of Neurosurgery Research Laboratory and
Regenerative Neuroscience Cluster, University of Bern and
University Hospital Bern, Switzerland
There is compelling evidence that stem and progenitor cells
secrete a wide array of trophic factors that could be exploited
for repairing injured tissues. We have previously reported
that the conditioned medium (CM) obtained from endothe-
lial progenitor cell (EPC) cultures promotes angiogenesis
and protects the striatal GABA immunoreactive (-ir) cell
viability against 3-NP toxicity. In the present study, we
tested the hypothesis that EPC-CM may support cortical and
midbrain neuronal cell function and / or survival. EPCs were
isolated from the peripheral blood of healthy human donors
and cultured in hypoxic conditions (1.5% O2) to stimulate
the secretion of growth factors. Primary cultures from fetal
rat embryonic (E14) cortex (CX) and ventral mesencephalon
(VM) were treated with EPC-CM and challenged by glucose
and serum deprivation (GSD) or MPPþ, respectively. First
we found that EPC-CM treatment resulted in a significantly
increased number of TH-ir cells in the VM as well as of
GABA-ir cells in the CX cultures. EPC-CM administration
exerted neuroprotection against GSD, an effect seen either
when EPC-CM was adminstered prior or subsequent GSD
incubation. Similarly, EPC-CM protected the dopaminergic
neurons in the in vitro model of Parkinson’s disease. Our
findings identified EPC-CM as a powerful tool to promote
viability and/or differentiation of cultured neuronal cells. In
conclusion our results suggest that EPC-CM might be useful
to expand the repertoire of available tools to tackle neuronal
degeneration.
This study was supported by the Swiss National Science
Foundation NRP63 and the HANELA Foundation,
Switzerland.
Characterizing the Role of Adropin in
Cerebral Aneurysm Pathophysiology
W. Dodd, K. Hosaka, and B. Hoh
University of Florida, College of Medicine, Department of
Neurosurgery, Gainesville, FL, USA
Cerebral aneurysms, which affect 3–5% of the population,
are a life-threatening neurovascular phenomenon. Altered
hemodynamics can initiate an inflammatory response lead-
ing to a weakening and localized bulging of the vessel wall,
resulting in an aneurysm. Rupture of an aneurysm is the
leading cause of hemorrhagic stroke and is associated with
up to 50% mortality. There remains a gap in knowledge
about the pathophysiology of aneurysm formation and rup-
ture, and about novel non-invasive treatments. Adropin is a
peptide hormone predominantly expressed in the liver and
central nervous system. Current literature suggests adropin
may affect vascular physiology through regulating eNOS
activity and nitric oxide bioavailability. We tested adropin’s
effect on aneurysm formation and rupture in mice. Briefly,
hypertension was induced through renal artery ligation and
angiotensin II infusion, and cerebral hemodynamics were
altered through unilateral carotid artery ligation. Mice were
then randomly allocated to receive 5 mg/day adropin, 50 mg/
day adropin, or 0.1% BSA vehicle, before receiving a dose of
elastase into the right basal cistern. Our preliminary data
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show a trend for 50 mg/day adropin decreasing aneurysm
formation in female mice (adropin: 33% (2 of 6) vs. vehicle:
86% (6 of 7), p¼0.10), with no effect on rupture rate (adro-
pin: 100% (2 of 2) vs. vehicle: 66.7% (4 of 6), p¼1.00). 5 mg/
day had no effect on formation in either female (adropin:
40% (4 of 10) vs. vehicle: 77.7% (7 of 9), p¼0.17) or male
mice (adropin: 42.8% (3 of 7) vs. vehicle: 77.7% (7 of 9),
p¼0.30), and also had no effect on rupture rate in females
(adropin: 100% (4 of 4) vs. vehicle: 85.7% (6 of 7), p¼1.00)
or males (adropin: 100% (3 of 3) vs. vehicle: 71.4% (5 of 7),
p¼1.00). More investigation is needed on various dosing
regimens and the mechanisms through which adropin exerts
its protective effects.
Sural Nerve Grafting as a Cell-based
Disease-modifying Therapy for Parkinson’s
Disease
N. El Seblani1,2,4, A. S. Welleford1,2, J. E. Quintero1,2,
F. Pomerleau1,2, P. Huettl1,2, C. G. Van Horne 1,2,3,
and G. A. Gerhardt1,2,3,4
1Department of Neuroscience, University of Kentucky, Lexington,
KY, USA
2Brain Restoration Center, University of Kentucky Medical Center,
Lexington, KY, USA
3Department of Neurosurgery, University of Kentucky, Lexington,
KY, USA
4College of Pharmacy, University of Kentucky, Lexington, KY, USA
Parkinson’s disease (PD) is the second most common neu-
rodegenerative disorder, with an annual incidence of 60,000
and costs of $ 25 billion in US. There is no current treatment
that can slow or reverse PD. We investigate a new cell-based
therapy to enhance the survival of the dying brain dopami-
nergic cells using Schwann cells (SC), which reside within
sural nerve grafts. Combined research shows that SCs can
transdifferentiate into neural repair cells mainly through c-
Jun signaling. Our current clinical trials (NCT01833364 and
NCT02369003) involve the implantation of the conditioned
sural nerve tissue to the substantia nigra in combination with
deep brain stimulation (DBS) for the treatment of advanced
PD. The SC grafts are harvested from the sural nerve of
participants undergoing DBS surgery. RNA sequencing of
the conditioned grafts showed transcriptome changes consis-
tent with the SC repair phenotype. Currently, 21 participants
have completed the two-year follow-up and demonstrated a
significant motor improvement using the MDS-UPDRS
scoring system. Postmortem studies of one participant
showed evidence for preservation of the dopaminergic cells
in the substantia nigra in response to the graft. To further
study the neurobiology of the SC grafts and how they may
affect the host brain tissue, we grafted human sural nerve
tissue into the brains of athymic nude rats, which we call
“Neuro-Avatars.” Each animal received a unilateral graft
into the dorsal striatum with a contralateral sham insertion.
The brains were processed 2 weeks and 6 months post
implantation. Immunostaining against human nuclear anti-
gen showed a substantial survival of the grafted cells in
addition to host responses to the grafts. Our future experi-
ments will study the use of similar nerve grafts in a
6-hydroxydopamine rat model of PD. In conclusion, regen-
erative changes in the peripheral nerve tissue may hold
therapeutic potential for the treatment of neurodegenerative
diseases like PD.
FKN Acts as a Double-Edged Sword
D. Finneran and K. Nash
University of South Florida, Molecular Pharmacology and
Physiology Department, Tampa, FL, USA
Inflammation is known to contribute to neurodegeneration
in a number of neurological disorders including Alzhei-
mer’s disease (AD), and represents a realistic and valuable
therapeutic target. Neuroinflammation can be modulated
by neuron–glial signaling through various soluble factors,
such as CD200, CD22, CD47 and fractalkine (FKN,
CX3CL1). For instance, loss of FKN signaling has been
shown to contribute to increased neurodegeneration in Par-
kinson’s disease (PD), amyotrophic lateral sclerosis (ALS)
and AD. We have also demonstrated that increasing the
expression of a soluble FKN (sFKN) is neuroprotective in
both PD and a tauopathy mouse model of neurodegenera-
tion, which is consistent with our and others’ findings that
increasing neuroinflammation in mouse models of PD and
tau deposition can exacerbate pathology. However, a
debate continues in the literature as to whether increased
sFKN is a benefit to tau pathology, thus confounding the
use of FKN as a therapeutic target for neurodegeneration.
We present data that shed light on the above divergence of
the use of FKN. We demonstrate that the commonly used
chemokine domain-only peptide of FKN (ckFKN) has a 10
fold decrease in receptor binding affinity compared with
sFKN, which is consistent with differences seen in calcium
signaling between ckFKN and sFKN. More intriguing is
that we have observed opposing effects with FKN concen-
tration, where at low concentrations (1 nM) FKN reduces
the microglial proinflammatory response, but at higher con-
centrations (>30 nM) FKN can begin to exacerbate the
proinflammatory response. Inhibitor studies show that this
proinflammatory signaling is likely through a noncanonical
receptor not currently identified or reported for FKN.
This is contrary to the current belief that FKN is an
anti-inflammatory molecule that signals through its sole
receptor CX3CR1. These data may clarify conflicts in the
literature and demonstrate that care must be taken with
respect to in vitro and in vivo studies using FKN, in turn
emphasizing the underlying need for better understanding
of the biology of FKN and its function.
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In Vivo Mapping of the Spatio-Temporal
Invasion of Immune Cells into Extracellular
Matrix Hydrogel in a Rat Model of Stroke
Using 19F Magnetic Resonance Imaging
H. Ghuman and M. Modo
University of Pittsburgh, McGowan Institute for Regenerative
Medicine, Department of Bioengineering, Department of
Radiology, Pittsburgh, PA, USA
Hydrogels formed from extracellular matrix (ECM) have the
potential to promote tissue restoration after a stroke. Infiltra-
tion of immune cells, especially macrophages, is a pivotal
event to drive biodegradation that leads to the invasion of
neural cells. However, spatio-temporal dynamics of the infil-
tration of immune cells into peri-infarct tissue and the ECM
hydrogel remain poorly understood. The tagging of immune
cells using perfluorcarbon (PFC) nanoemulsions affords
their in vivo visualization using 19F magnetic resonance
imaging (MRI). Rats with middle cerebral artery occlusion
(MCAo), a model of ischemic stroke, were implanted with
ECM hydrogel 14 days after infarction using MRI guidance
to define the site and volume of injection. One day prior to
the ECM implantation, animals were injected with PFC
through the tail vein and baseline 19F MR image was
acquired to verify the injection and potential passive influx
to the stroke-damaged brain. However, no PFC influx to the
brain was evident at this time point. “Time lapse” imaging
over 24 hours indicated that no immune cells invaded the
brain for 6 hours after ECM implantation, although a major
infiltration in the scalp incision wound was evident within 1
hour after surgery. Infiltration of immune cells was first
evident in the peri-infarct area at 9 hours post-implantation
with subsequent invasion into the ECM hydrogel. By 24
hours a major invasion of immune cells into the ECM hydro-
gel was evident, as verified by immunohistochemistry in
post-mortem tissue. Histological analyses revealed that
almost all invading macrophages were labeled with PFC,
indicating that these were peripheral macrophages rather
than brain-derived microglia. ECM hydrogel implantation
therefore induces a delayed invasion of macrophages into
the stroke-damaged brain through the peri-infarct area that
is governed by peripheral macrophages effecting the initial
biodegeneration events that lead to brain tissue restoration.
Phase I Clinical Trial Update: Human
Neural Stem Cell Treatment for
Parkinson’s Disease
R. Gonzalez1, I. Garitaonandia1, G. Sherman1,
A. Semechkin1, E. Braine2, A. Shahrul2, G. Nair2,
A. H. Evans2, and R. A. Kern1
1Intl. Stem Cell Corp, Carlsbad, CA, USA
2The Royal Melbourne Hospital, Parkville, Australia
Parkinson’s disease (PD) is a devastating neurodegenerative
disease with progressive degeneration of dopaminergic (DA)
neurons in the substantia nigra pars compacta. There are over
10 million people afflicted with PD and the yearly mortality
rate is more than 100,000 worldwide. Unfortunately none of
the available treatment options have the potential to restore
the damaged nigrostriatal pathway. Cell-based therapies
have shown considerable promise because they can achieve
significant biochemical and clinical improvements for sev-
eral years in some patients. We have demonstrated in pre-
clinical PD models that transplantation of human
parthenogenetic derived neural stem cells (ISC-hpNSC) pro-
motes behavioral recovery and increases DA levels, as well
as DA neuron innervation and number. Intra-nigrostriatal
administration of clinical grade ISC-hpNSC is safe, well
tolerated, reduces inflammation, and provides neurotrophic
support and neuroregeneration to the nigrostriatal pathway.
We are conducting a First-In-Human study to evaluate the
safety and functional activity of ISC-hpNSC, making it the
world’s first pluripotent stem cell-based therapy for PD
(ClinicalTrials.gov: NCT02452723). This is a single-arm,
open-label, Phase I study evaluating three dose regimens
of 30, 50 and 70 million ISC-hpNSC. There are 12 patients
in this study divided into 3 cohorts of 4 patients each.
Patients receive immunosuppression and stereotactic bilat-
eral injections of 7 cell deposits per hemisphere into the
caudate nucleus, putamen, and substantia nigra. Patients are
evaluated for 12 months with a 5-year long-term follow-up.
The primary endpoint of the study is to assess the incidence
of treatment-emergent adverse events. Secondary endpoints
evaluate efficacy by measuring the change from baseline in
18F-dopa PET, UPDRS, PDQ-39, BDI, CGI, QUIP-RS,
AIMS and MOCA. Eleven patients have been successfully
transplanted with 30, 50 and 70 million ISC-hpNSC, respec-
tively. Delivery of ISC-hpNSC to the striatum and substantia
nigra went according to plan without intraoperative compli-
cations. No serious adverse events (SAE) associated with
ISC-hpNSC or the immunosuppression regimen has been
reported. No graft-induced dyskinesia or evidence of tumors,
inflammation or infection has been reported. Six month anal-
ysis of 18F-dopa PET scans and neurological scores from the
first and second cohort will be presented. In summary,
interim data shows that administration of ISC-hpNSC is safe
and has the potential to repair the nigrostriatal pathway.
Potential Benefits of Environmental
Enrichment in a Rodent Model of
Tauopathy
R. C. Gorzek1,2, A. Mangahas2, S. Osting1,
and C. Burger1
1Department of Neurology, University of Wisconsin-Madison,
Madison, WI, USA
2College of Letters and Sciences, University of Wisconsin-
Madison, Madison, WI, USA
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An astounding 1 in 3 senior citizens die with Alzheimer’s
disease (AD) and Alzheimer’s-related dementias, yet no reli-
able treatments for these disorders exist. AD in humans has
multiple underlying molecular pathologies including beta-
amyloid plaque formation and hyper-phosphorylation of
microtubule-associated protein tau. Research in rats and
humans suggests environmental enrichment (EE) preserves
cognitive function during aging, but the molecular mechan-
isms are largely unknown. Results from our laboratory
demonstrate that 1 month of EE results in an activity-
dependent increase in phosphorylated p70S6 kinase (p-
p70S6 K) for 30 minutes following synaptic stimulation in
the hippocampus. This improves learning and memory in
young and aged rats. p70S6 K is involved in protein synth-
esis important to learning, memory, and synaptic plasticity.
Curiously, human AD brains show constitutive phosphory-
lation of p70S6 K, suggesting that p70S6 K is dysregulated
in AD and may result in adverse effects on cognitive func-
tion. We predict EE will have a protective effect by regulat-
ing phosphorylation levels of p70S6 K in a rodent model of
tauopathy. Here, we delivered wild-type human tau using
adeno-associated virus (AAV-Tau4 R) to the hippocampus
of adult rats. We found a 1.3-fold increase in hippocampal
tau levels 15 days following viral vector injection and a 3.4-
fold increase in basal levels of p-p70S6 K. To test the effects
of EE in alleviating the p-p70S6 K dysregulation in this
model, we will house animals in EE or standard conditions
(SC) for 1 month prior to AAV injection. Fifteen days post-
injection, we will perform behavioral testing, and quantify
basal and synaptic activity-dependent p-p70S6 K levels. We
hypothesize that EE AAV-Tau4R-injected animals will
show normal basal and increased activity-dependent p-
p70S6 K levels, and improved learning compared to SC
injected animals. The results from this study will provide
knowledge about the therapeutic value of EE in regulating
molecular pathways contributing to age-related disorders.
Exosomal Biomarkers in Brain Injury and
Disease
L. Granholm1, A. Ledreux1, E. Hamlett2, A. Gilmore1,
E. Head3, A. Butterfield4, M. Carmona-Iragui5,
J. Fortea5, M. Margittai6, and E. Mufson7
1Knoebel Institute for Healthy Aging, University of Denver,
Denver, CO, USA
2Department of Pathology and Laboratory Medicine, Medical
University of South Carolina, Charleston, SC, USA
3Department of Pathology & Laboratory Medicine, University of
California, Neuroscience Research Facility, Irvine, CA, USA
4Sanders-Brown Center on Aging, University of Kentucky,
Lexington, KY, USA
5Memory Unit, Department of Neurology, Hospital de la Santa
Creu I Sant Pau, Universitat Autonoma de Barcelona, Barcelona,
Spain
6Department of Chemistry and Biochemistry, University of
Denver, Denver, CO, USA
7Alzheimer’s Program, Barrow Neurological Institute, Phoenix, AZ,
USA
Individuals with Down syndrome (DS) exhibit Alzheimer’s
disease (AD) neuropathology and dementia early in life, with
almost complete penetrance. Reliable blood biomarkers are
lacking and could improve early diagnosis and confirm
effects of experimental therapeutics. Extracellular vesicles
(EVs) including exosomes are nanosized particles that are
secreted by all cell types and are present in all bodily fluids.
Exosomes contain bioactive molecules including proteins,
mRNA, miRNA, and lipids that can be used for signaling
and transportation across the neuraxis and between individ-
uals. We have examined the presence of AD-related biomar-
kers in the cargo of exosomes derived from neurons obtained
from blood samples of people with DS at different ages, and
compared with age-matched controls and patients with AD.
Similar biomarkers have also been examined in exosomes
from athletes with one or several concussions, to determine
whether repeated mild traumatic brain injuries (mTBIs) lead
to elevated brain injury biomarkers long term or at different
intervals post-concussion. Further, we have demonstrated
that exosomes derived from patients with DS and AD can
develop tangles containing hyperphosphorylated Tau (p-
Tau) when injected into the hippocampus of wild-type mice.
These findings suggest that neuron-derived exosomes can be
developed into a novel and reliable biomarker method, both
for mTBI and AD, and that AD pathology can spread from
exosomes into the brain between individuals following injec-
tion. Thus, the novel exosome methodology can provide new
answers as to how AD pathology can spread between adja-
cent brain regions.
This work was funded by the National Institutes on Aging
and the Alzheimer’s Association.
Reparative Effects of Stem Cell Factor and
Granulocyte Colony-Stimulating Factor in
Aged APP/PS1 Mice
X. Guo, Y. Liu, S. Longo, and L-R. Zhao
Department of Neurosurgery, SUNY Upstate Medical University,
Syracuse, NY, USA
Alzheimer’s disease (AD) is the most common cause of
dementia among the elderly. Increased amyloid-beta (Ab)
aggregation and neuroinflammation are crucially involved
in the pathogenesis of AD. Microglia, the primary innate
immune cells of the brain, play a key role in Ab clearance
and neuroinflammation. Our previous studies have demon-
strated that administration of two hematopoietic growth
factors, stem cell factor (SCF) and granulocyte colony-
stimulating factor (G-CSF), in 9-month-old male amyloid
precursor protein/presenilin 1 (APP/PS1) mice leads to
reductions of cerebral Ab aggregation. To determine the
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therapeutic efficacy of SCFþG-CSF in aged APP/PS1 mice,
in this study, 12-day injections of SCFþG-CSF were given
to 25-month-old male APP/PS1 mice. Our data revealed that
the percentage area, the number, and the size of Ab plaques
in both the cortex and hippocampus were significantly
reduced by SCFþG-CSF treatment. The capillaries with
Ab deposits were also significantly decreased in the cortex
and hippocampus after SCFþG-CSF treatment. In addition,
the association of triggering receptor expressed on myeloid
cells 2/ionized calcium-binding adaptor molecule 1
(TREM2þ/Iba-1þ) microglia with Ab plaques was signifi-
cantly increased by SCFþG-CSF treatment. Importantly,
increased P2RY12 positive microglia were seen in both the
cortex and hippocampus of the SCFþG-CSF-treated APP/
PS1 mice. SCFþG-CSF treatment also led to significant
increases of the branches in the purinergic receptor P2Y,
G-protein coupled, 12 (P2RY12)þmicroglia. The decreased
pro-inflammatory molecule nitric oxide synthase 2 (NOS2)
and increased anti-inflammatory molecule interleukin 4
(IL4) were observed in the SCFþG-CSF-treated APP/PS1
mice. Moreover, SCFþG-CSF treatment prevented the loss
of microtuble-associated protein 2 (MAP2)þ dendrites in the
cortex and hippocampus of the aged APP/PS1 mice. These
findings suggest that SCFþG-CSF treatment in aged APP/
PS1 mice increases Ab clearance, reduces neuroinflamma-
tion and prevents dendritic degeneration. The beneficial
effects of SCFþG-CSF in aged APP/PS1 mice are associated
with the modulation of microglial activation. This study
sheds new light on the therapeutic potential of SCFþG-
CSF in AD.
This study was supported by NIH/NIA (R01AG051674).
The Contribution of Stem Cell Factor and
Granulocyte Colony-Stimulating Factor in
Reducing Neurodegeneration and
Promoting Neural Network Reorganization
after Traumatic Brain Injury
J. He, T. Russell, S. Longo, and L-R. Zhao
Department of Neurosurgery, SUNY Upstate Medical University,
Syracuse, NY, USA
Traumatic brain injury (TBI) is a major cause of death and
disability in young adults worldwide. TBI-induced long-
term cognitive deficits represent a growing clinical problem.
The aim of this study was to determine the effects of stem
cell factor (SCF) and granulocyte colony-stimulating factor
(G-CSF) on long-term neurological outcomes, neurodegen-
eration, and neural network reorganization after TBI. The
controlled cortical impact (CCI) model of TBI, which
severely damages the motor cortex, was used in this study.
TBI was performed in 8-week-old male C57BL mice. The
combination treatment of SCF and G-CSF (SCFþG-CSF)
was initiated 3 weeks after induction of TBI. Neurobeha-
vioral tests were performed for examination of neurological
deficits before treatment as well as 2 and 6 weeks after
treatment. Spatial learning and memory was evaluated
through the Morris Water Maze test, and the Rotarod test
was used for examining motor function. Hematoxylin and
eosin (H&E) staining was utilized to calculate the tissue loss
volume. Neurodegeneration was determined by Fluoro-Jade
C Staining. Immunohistochemistry of SMI-312 was per-
formed to assess the axons. We found that SCFþG-CSF
treatment significantly reduced latency to platform (escape
latency) in Morris Water Maze at 6 weeks post-treatment.
Two weeks after treatment, TBI-vehicle-treated mice
showed significant increases of escape latency as compared
with sham controls, while the escape latency of SCFþG-
CSF-treated TBI mice did not show differences from the
sham controls. Before treatment, there were no differences
in neurobehavioral tests between the two groups of TBI mice
that would be treated with/without SCFþG-CSF. SCFþG-
CSF treatment did not change the performance of Rotarod
and the tissue loss volume after TBI. However, TBI-induced
neurodegeneration in the contralateral cortex was signifi-
cantly reduced by SCFþG-CSF. In addition, TBI-induced
abnormal increases of SMI-312 positive axons in the ipsilat-
eral cortex adjacent to the TBI cavity were prevented by
SCFþG-CSF treatment. These data suggest that SCFþG-
CSF treatment in the late subacute phase of TBI improves
cognitive function, reduces neurodegeneration, and prevents
post-TBI overgrowth of cortical axons.
This study was supported by Department of Veterans
Affairs (I01 RX002125).
(-)-Phenserine Ameliorates Contusion
Volume Loss, Neuroinflammation, and
Behavioral Impairments Induced by
Traumatic Brain Injury in Mouse
S-C. Hsueh1,2,3*, Y. Luo1,2,3, N. H. Greig1,6,
B. J. Hoffer1,2,3, J-Y. Wang1,2, J. P. Miller3,
and Y-H. Chiang1,2,4,5
1The Ph.D. Program for Neural Regenerative Medicine, College of
Medical Science and Technology, Taipei Medical University,
Taipei, Taiwan
2Center for Neurotrauma and Neuroregeneration, Taipei Medical
University, Taipei, Taiwan
3Department of Neurosurgery, Case Western Reserve University
School of Medicine, Cleveland, OH, USA
4Department of Neurosurgery, Taipei Medical University
Hospital, Taipei, Taiwan
5Department of Surgery, School of Medicine, College of Medicine,
Taipei Medical University, Taipei, Taiwan
6Translational Gerontology Branch, Intramural Research Program,
National Institute on Aging, National Institutes of Health,
Baltimore, MD, USA
Traumatic brain injury (TBI) is one of the major causes of
death and disability and affects an estimated 10 million
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people worldwide. Currently, there is no approved drug for
ameliorating the pathological processes of TBI. Previous
studies have shown that (-)-phenserine (phen), an acetylcho-
linesterase inhibitor originally designed as a candidate drug
for Alzheimer’s disease (AD), was tested in clinical Phase II
studies and showed no adverse effects. Besides its anti-
amyloid activity in AD, our previous data also showed phen
can prevent several neurodegenerative mechanisms as well
as reduce the cognitive impairments induced by mild TBI
using a weight-drop mouse model. In this study, we used a
mouse model of moderate to severe TBI induced by con-
trolled cortical impact to assess the effects of phenserine on
somatosensory functions. Animals were treated with phen
(2.5 mg/kg, BID) by intraperitoneal injection for 5 days
started from injury day at a clinically translatable dose and
the effects were evaluated by behavioral and histological
examinations at 1 and 2 weeks post-injury. Phen signifi-
cantly attenuated TBI-induced contusion volume, enlarge-
ment of the lateral ventricle, and behavioral impairments
in sensorimotor functions. The morphology of microglia was
shifted to an active form from a resting form after TBI, and
phen dramatically mitigated the population ratio of activated
to resting microglia, suggesting that phen also mitigates neu-
roinflammation following TBI. Taken together, these results
show that post-injury treatment with phen over 5 days sig-
nificantly reduced the lesion volume and the enlargement of
the lateral ventricle caused by TBI. In addition, phen effec-
tively reduced sensory and motor deficits at 7–14 days post-
injury. These data suggest a potential development of this
compound for clinical use in TBI therapy.
Direct Conversion of Astrocytes to
Neurons Enhances Neuronal Repair and
Functional Recovery after Ischemic Stroke
M. Jiang, S. P. Yu, and L. Wei
Department of Anesthesiology, Emory University School of
Medicine, Atlanta, GA, USA
Regenerative therapies, including cell transplantation, have
been extensively investigated in recent years for the treat-
ment of central nervous system (CNS) injuries, such as
stroke. In the present investigation, we explored an innova-
tive stroke treatment of reprogramming endogenous astro-
cytes into induced neurons (iNeurons) for neuronal repair
after focal ischemic stroke. A mCherry-tagged NeuroD1 len-
tivirus was generated under a mouse glial fibrillary acidic
protein (GFAP) promoter for in vitro and in vivo infections.
Cultured astrocytes expressing mCherry/NeuroD1 adopted
neuronal morphology and expressed neuronal markers Tuj-
1, NeuN, and synaptic proteins 2–4 weeks after infection.
Proliferation was drastically reduced compared with control
cultures. Converted cells were found to have developed sig-
nificantly longer processes (>20–100 mM) when inspected
at 6 weeks after infection. A focal ischemic stroke of the
right sensorimotor cortex was induced in adult GFAP-Cre x
Rosa-yellow fluorescent protein (YFP) mice. Astrocytes
from this mouse remained YFP positive regardless of cell
phenotype. The lentivirus containing mCherry-NeuroD1 and
the GFAP promoter was injected into the peri-infection
region 3 days after stroke, which transduced *10% of reac-
tive astrocytes accumulated in the peri-infarct region. Six
weeks later, converted cells were identified by the co-
labeling of YFP (the astrocyte origin marker), mCherry
(the marker for NeuroD1 transduction), and NeuN
(mature neuron marker). Around *60% of converted
cells expressed NeuN and showed neuronal morphology.
Western blot assay of the peri-infarcted region detected
significantly higher levels of brain-derived neurotrophic
factor (BNDF) and fibroblast growth factor 10 (FGF10)
in NeuroD1-transfected mice compared with animals that
received empty vectors. Meanwhile, the area of gliosis
noticeably decreased. Stroke mice that received NeuroD1
transfection performed significantly better in the rotarod
test and corner test, and a preventive effect was observed
with regard to chronically developed depressive behavior
4 months after stroke. Thus, astrocyte-to-neuron repro-
gramming enforces parenchymal neurogenesis and helps
to improve functional recovery after stroke.
Active Immunization with Tau Epitope in a
Mouse Model of Tauopathy Induced Strong
Antibody Response Together with
Improvement in Short Memory and Tau
Pathology
A. Joly Amado1, H. Davtyan2, K. Serraneau1,
K. Zagorksi2, M. N. Gordon1, D.H. Cribbs3,
A. Ghochikyan2, N. Petrovsky4, M. G. Agadjanyan2,
and D. Morgan1
1University of South Florida Health, Byrd Alzheimer’s Institute,
Tampa, FL, USA
2The Institute for Molecular Medicine, Huntington Beach, CA,
USA
3University of California Irvine, Irvine, CA, USA
4Flinders Med. Ctr., Bedford Park, Adelaide, Australia
Abnormal tau hyperphosphorylation and its accumulation
into neurofibrillary tangles are a hallmark of tauopathies,
which are neurodegenerative disorders that include Alzhei-
mer’s disease (AD). Tau immunotherapy has therefore been
proposed as a new therapeutic approach to AD. The aim of
this study was to test if active immunotherapy with a highly
immunogenic tau epitope in a mouse model of tau deposition
was capable of reducing levels of tau pathology in the brain
and improving cognition. Tg4510r mice, carrying the human
four-repeat tau with the P301 L mutation (4R0 N tauP301 L)
and the CamK-II tetracycline-controlled transactivator pro-
tein were used. Male and female transgenic rTg4510 mice (3
months old; n¼36) were subdivided into 3 groups (n¼12 per
group) and received intramuscular injections of tau vaccine,
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Abeta vaccine, or adjuvant only. Non-transgenic and tet only
littermates (tetracycline-controlled transactivator protein
expressing mice) were used as control groups for beha-
vioral testing and anatomy comparisons. All groups
received three injections in alternating weeks and were
boosted an additional three times (4 weeks apart) for a total
of 7 injections. Mice were subjected to behavioral testing
including open field, Y maze, radial arm water maze and
novel object recognition by an observer blind to the treat-
ment/genotype of the mice in order to evaluate learning,
memory, and general activity. Active immunization
induced strong humoral immune responses in both non-
transgenic and transgenic mice. Mice vaccinated with the
tau epitope displayed an improvement in short-term mem-
ory when compared with adjuvant- and Abeta-treated mice
during novel object recognition test. Hyperphosphorylated
tau but not total tau was also reduced in the cortex of tau-
vaccinated mice compared with Abeta-treated mice. Alto-
gether, these data indicate that active immunotherapy with
tau epitope was effective in improving cognition and reduc-
ing pathology in a mouse model of tau deposition.
Human Embryonic Retinal Pigment
Epithelial Cell (hRPEC) Grafts Provide
Immunomodulation of the Host
Microenvironment through Secreted
Cytokines
A. Kim1, T. Cayton1, T. Subramanian3, P. S. Grigson2
and K. Venkiteswaran3
1Penn State University College of Medicine (PSU-COM), Hersehy,
PA, USA
2Neural and Behavioral Sciences, PSU-COM, Hershey, PA, USA
3Department of Neurology, PSU-COM, Hershey, PA, USA
Human embryonic retinal pigment epithelial cell (hRPEC)
xenotransplantation in animal models of Parkinson’s dis-
ease (PD) and high-dose cocaine self-administration have
been shown to produce behavioral improvements without
the need for immunosuppression. In these experiments,
hRPEC xenografts did not evoke an inflammatory response
that is seen with other central nervous system (CNS) xeno-
grafting paradigms. hRPEC graft survival was excellent
without any inflammatory responses in the dorsal striatum
or nucleus accumbens. To understand the mechanism
through which the hRPEC xenografts provide immunomo-
duation and avoid deleterious inflammatory responses, we
tested the effects of secreted cytokines from hRPECs on
activated microglia and T lymphocytes using hRPEC-
conditioned medium (hRPEC-CM). Murine microglial
cells prepared from postnatal day 0–2 rats and cultured in
vitro were activated using lipopolysaccharide (LPS)/inter-
feron-g (IFN-g), and were exposed to hRPEC-CM. IFNg/
LPS activation of microglial cells incubated in fresh media
resulted in a robust increase in expression of all the three
cytokines tested, when compared with the cells, which were
not activated (p<0.001). Expression of mRNA for interleu-
kin-1beta (IL-1b) was increased 5.3 fold, tumor necrosis
factor-a (TNFa) 2.5 fold and IL-6 6.3 fold as a result of
IFNg/LPS activation. In the IFNg/LPS activated cells,
expression of all three cytokines were significantly reduced
after incubation with hRPEC-CM when compared with the
cells incubated with fresh media. IL-1b expression was
reduced 2.8 fold (p<0.019), while interleukin-6 (IL-6)
expression was decreased 2.6 fold (p<0.001) and TNF-a
expression was reduced 1.6 fold (p<0.001). Immunomodu-
latory effects of hRPEC-CM and hRPEC monolayer on
activated human T-cell proliferation were also assessed in
vitro using a tritiated thymidine incorporation assay, which
showed substantial suppression of T-cell proliferation by
30% with conditioned medium, and when incubated with
RPE monolayer the proliferation was suppressed by 80%.
These results show that hRPEC xenografts make the graft
microenvironment more receptive, allowing for its effec-
tive use without the need for continuous life-long
immunosuppression.
Unilateral Optogenetic or Chemogenetic
Inhibition of the Nigrostriatal Pathway
Causes Reversible Hemiparkinsonism that
is not Associated with Spontaneous or
Levodopa-Induced Dyskinesias
K. Le1, S. Chinniah1, V. Iyer1, N. Patel2, C. Lieu1,
M. Pennock1, E. Handley1, A. Zenerowitz1, E. Dickey1,
S. Savaliya1, T. Subramanian1, and K. Venkiteswaran1
1Department of Neurology, Penn State College of Medicine,
Hershey, PA, USA
2Department of Neurosurgery, Penn State College of Medicine,
Hershey, PA, USA
Levodopa (L-dopa) provides effective relief in Parkinson’s
disease (PD) but in the long term causes levodopa-
induced dyskinesias (LID). The loss of continuous dopa-
minergic stimulation (CDS) hypothesis would predict that
hemiparkinsonian (HP) patients and HP animals would
develop unilateral LID. However, our studies show that
HP rats and monkeys with preserved interhemispheric
nigrostriatal fibers do not develop LID. This suggests that
loss of interhemispheric nigrostriatal connections may be
critical for the genesis of LID. We tested the hypothesis
that unilateral nigrostriatal will lead to reversible HP that
will not be associated with dyskinesias. We used recom-
binant viral vectors to conditionally express eNpHR3.0 or
hM4Di to cause unilateral inhibition of the left nigrostria-
tal pathway. In model #1, Sprague Dawley rats and in
model #2 transgenic TH-Cre rats were used. In both mod-
els, recombinant virus AAV5-Ef1a-DIO-eNpHR3.0-EYFP
or AAV8-hSyn-DIO-hM4Di-mCherry was injected into
the left substantia nigra pars compacta (SNpc). A cre-
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mediated switch, AAV2-Ef1a-mCherry-IRES-WGA-Cre,
was injected unilaterally into the left striatum of model
#1 animals. Animals were repeatedly tested for onset and
reversal of right HP (RHP) state. The eNpHR3.0-treated
animals served as controls for the hM4Di-treated animals
and vice versa. In the chemogenetic cohorts, animals
were tested using both Clozapine-n-oxide (CNO) and a
novel high-affinity ligand JH37160. With both com-
pounds, animals showed a mean 75% reduction of the
vibrissae-evoked forelimb placement score (VEFP,
p<0.05). Additionally, the optogenetic cohort also showed
a similar 75% reduction in their VEFP score. Other par-
kinsonian behavioral tests were also similarly effective to
document reversible HP states. In both models, RHP was
completely reversible with no residual parkinsonism or
adverse events and histological verification of unilateral
gene expression. Repeated induction of RHP or RHP with
L-dopa treatments failed to elicit dyskinesias. These find-
ings support the notion that preservation of interhemi-
spheric nigrostriatal fibers and dopaminergic synapses
will mitigate/prevent LID in PD.
Intravenously Administered Human Neural
Stem Cell-Derived Extracellular Vesicles
Ameliorate Cranial Radiation-Induced
Brain Injury
R. J. Leavitt, M. M. Acharya, J. E. Baulch, N. Ru,
M. C. Angulo, L. Apodaca, L. Yu, and C. L. Limoli
Department of Radiation Oncology, University of California Irvine,
Irvine, CA, USA
Cognitive deficits following clinical radiation therapy for
central nervous system tumors are progressive and debil-
itating to surviving cancer patients, causing a deteriora-
tion of quality of life. Using an immunocompromised rat
model, we previously demonstrated that cranial engraft-
ment of human neural stem cell (hNSC)-derived extracel-
lular vesicles (EV) ameliorated radiation-induced
cognitive dysfunction, neuroinflammation, and neuron
structure damage. Building on those observations, we
showed that those same beneficial effects of EV treatment
are conferred to cranially irradiated (IRR) immunocom-
petent rodents without the need for immunosuppression or
risk of teratoma formation. Furthermore, toward advance-
ment to a clinically translatable application, we demon-
strated that injection of EV into the retro-orbital venous
sinus (IV injection) represents an effective and signifi-
cantly less invasive EV delivery strategy as compared
with the previously used intra-hippocampal route of injec-
tion. Behavioral analyses of these IV injected animals, 1
and 6 months later, demonstrated that the EV were effec-
tive in the rescue of IRR-induced cognitive deficits. We
also observed significantly reduced microglial activation
and synaptic protein loss. In addition, RNA-seq data from
the mouse hippocampi uncovered specific neuronal sig-
naling, synaptic and microglial genes, and pathways
altered in the irradiated group and rescued in the treat-
ment groups. The miRNA microarray of hNSC-derived
EV was integrated with the RNA-seq data to suggest a
role for miR-124 in the mechanism of EV-mediated reme-
diation of the irradiated brain. Collectively, these studies
represent a key advancement in developing an evidence-
based clinical treatment strategy that will ease the neuro-
cognitive side effects of cranial IRR.
Gutting the Parkinson’s Brain of
Inflammation: Human Umbilical Cord
Blood Stem Cells and Plasma Target
Gut–Brain Axis
J. Y. Lee1, H. Nguyen1, J. Tuazon1, J. Ehrhart2,
J. Holland2, P. R. Sanberg1, and C. V. Borlongan1
1Center of Excellence for Aging and Brain Repair, Department of
Neurosurgery and Brain Repair, University of South Florida
Morsani College of Medicine, Tampa, FL, USA
2Saneron CCEL Therapeutics Inc., Tampa, FL, USA
Current therapies for Parkinson’s disease (PD), including
both L-3,4-dihydroxyphenylalanine (L-DOPA), and clini-
cal trials investigating dopaminergic cell transplants, have
generated mixed results with the eventual induction of
dyskinetic side effects. Although human umbilical cord
blood (hUCB) stem/progenitor cells present no or minimal
capacity of differentiation into mature dopaminergic neu-
rons, their transplantation significantly attenuates parkin-
sonian symptoms likely via bystander effects, specifically
stem cell graft-mediated secretion of growth factors, anti-
inflammatory cytokines, or synaptic function, altogether
promoting brain repair. Recognizing this non-cell replace-
ment mechanism, we examined here the effects of
intravenously transplanting a combination of hUCB and
plasma (from the same cord blood unit) into the 6-
hydroxydopamine (6-OHDA)-induced rat model of PD.
Animals received repeated dosing of either 4  106 hUCB
cells with plasma or vehicle at 3, 5, and 10 days after
stereotaxic 6-OHDA lesion, then behaviorally and immu-
nohistochemically evaluated over 56 days post-lesion.
Compared with vehicle treatment, transplantation with
hUCB and plasma significantly improved motor function,
gut motility, and survival of dopaminergic neurons in the
substantia nigra pars compacta (SNpc), which coincided
with reduced pro-inflammatory cytokines in both the SNpc
and the intestinal mucosa and dampened inflammation-
associated gut microbiota. These novel data directly impli-
cate a key pathological crosstalk between the gut and
brain, ushering a new avenue of therapeutically targeting
the gut microbiome with hUCB-derived stem cells and
plasma for PD.
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of this Abstract.
Structural and Functional MRI as
Biomarkers for Repair Processes Following
Stem Cells Therapy of White Matter
Stroke
S. Lepore1, I. L. Llorente2, I. Pham2, W. Lowry3,
J. Schoenfield1, S. T. Carmichael2, and N. G. Harris1
1Department of Neurosurgery, School of Medicine, University of
California Los Angeles, Los Angeles, CA, USA
2Department of Neurology, School of Medicine, University of
California Los Angeles, Los Angeles, CA, USA
3Department of Molecular Cell & Developmental Biology, School
of Medicine, University of California at Los Angeles, Los Angeles,
CA, USA
Subcortical white matter stroke (WMS) constitutes up to
30% of all stroke subtypes and consists of a range of patho-
physiological events, from small infarcts to more diffuse
areas of damage. There is currently no specific therapy for
WMS, either to prevent disease progression, or to improve
the brain’s ability to recover from this insult. The use of
stem cells is an emerging therapy for neural repair in WMS.
Skin fibroblast-derived induced pluripotent stem cells
(iPSCs) can be differentiated toward glial enriched pro-
genitors (GEPs) and may be used to enhance endogenous
repair mechanisms. iPS-GEPs are suited for brain repair
because they differentiate into immature astrocytes, the
most affected neuroglial cell population after WMS. Previ-
ous pre-clinical studies have shown that iPS-GEPs both
replace cells lost in WMS and induce surviving cells to
repair damaged axons. Stem cell therapy in WMS is ideally
suited for the development of a non-invasive biomarker of
tissue repair. WMS regions are currently imaged as hyper-
intensity on T2 magnetic resonance imaging (MRI), or
altered diffusivity using diffusion weighted MRI. However,
there are currently no in vivo imaging biomarkers of the
brain repair process. Therefore, in this study, we used a
recently developed mouse model of WMS to establish a
quantitative measure of WM structure in vivo using diffu-
sion tensor imaging metrics (FA, AD, RD and MD)
throughout the repair processes that is produced by iPS-
GEPs therapy. Additionally, we explored the use of resting
state functional MRI as a biomarker to provide a readout of
functional enhancement in the cortex during the brain
repair process. The development of a biomarker of iPS-
GEPs repair in WMS will substantially accelerate clinical
application of this iPS therapy, by enabling clinical trials to
be conducted with smaller sample sizes and shorter dura-
tions compared with current standards that use cognitive
outcome measures.
Human iPS-Derived Interneurons Enhance
Functional Recovery after Cortical Stroke
I. L. Llorente1, T. Segura3, W. E. Lowry2
and S. T. Carmichael1
1Department of Neurology, David Geffen School of Medicine,
University of California Los Angeles, Los Angeles, CA, USA
2Department of Molecular, Cell and Developmental Biology,
University of California Los Angeles, Los Angeles, CA, USA
3Department of Biomedical Engineering, Duke University,
Durham, NC, USA
Stroke is the leading cause of adult disability. There are no
therapies that promote recovery from this disorder. Cell
transplantation in cortical stroke has utilized neural pro-
genitors in early differentiation stages; however, these have
often shown poor survival, migration, and differentiation
after transplant. The present studies develop a different
paradigm of cell transplantation in cortical stroke by using
induced pluripotent stem cell-derived (iPS)-interneurons.
Interneuron transplantation for diseases other than stroke
shows that these cells survive in hostile brain environ-
ments, migrate widely within the adult central nervous
system (CNS), and integrate into the adult brain circuitry.
iPS-interneurons were produced using small molecule inhi-
bitors of Wnt, transforming growth factor-b (TGF-b), and
bone morphogenetic protein (BMP), and are therefore
termed iPS-3i. The iPS-3i cells progress through a molecu-
lar expression pattern resembling median ganglionic emi-
nence (MGE) cells. iPS-interneurons were transplanted into
the stroke cavity with a hyaluronan (HA) hydrogel contain-
ing clustered vascular endothelial growth factor (VEGF)
immobilized on heparin nanocapsules to reduce transplant
stress from the direct transplantation into the stroke cavity.
Transplants were done at either the subacute or chronic
stage after cortical stroke (7 days vs. 1 month after stroke).
In order to assess motor deficit and recovery after stroke,
gridwalking and pasta-handling tasks were performed. We
report significant behavioral recovery in mice suffering
from motor cortex stroke when the HA-hydrogelþ VEGF
nanoparticles, and iPS-3i were injected simultaneously into
the stroke core. Confocal images of ipsilateral tissue show
concurrent structural changes while electrophysiological
recordings demonstrate integration of iPS-3i into pre-
existing circuitry. Notably, these results are seen when
treatment is administered in either the subacute or chronic
stage of stroke. Overall findings provide promising evi-
dence of a stem cell treatment for stroke unique to the
subtype iPS-3i.
Supported by CIRM DISC1-08723.
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Neural Stem Cell Function During Aging:
Critical Periods, Regulation, Therapeutic
Opportunities
L. Madhavan1,5,6, M. J. Corenblum1,6, S. Ray2,
A. Anandhan1, 3, A. Reed2, K. R. Kirwan2,
D. D. Zhang3, and C. A. Barnes1,4,5
1Department of Neurology, University of Arizona, Tucson, AZ,
USA
2Neuroscience and Cognitive Science Program, University of
Arizona, Tucson, AZ, USA
3Pharmacology and Toxicology, University of Arizona, Tucson, AZ,
USA
4Departments of Psychology and Neuroscience, University of
Arizona, Tucson, AZ, USA
5Evelyn F McKnight Brain Institute, University of Arizona, Tucson,
AZ, USA
6Center for Innovation in Brain Science, University of Arizona,
Tucson, AZ, USA
Understanding neural stem cell (NSC) biology in the context
of aging has significant implications toward developing ther-
apeutics for age-related neurodegenerative disorders. As
aging progresses, it is known that the regeneration of NSCs
in the two major neurogenic niches—the subventricular zone
(SVZ) in the forebrain and the subgranular zone (SGZ) of the
hippocampus—undergoes a notable decline. Our recent
work indicates that while NSC function, in both the SVZ
and the SGZ, continuously decreases with advancing age,
there is a critical time period during middle-age (13–15 mos)
when a striking reduction in NSC survival and regeneration
occurs (Corenblum et al, 2016; Ray et al, 2018). These stud-
ies also determined the reduced expression of the redox tran-
scription factor, nuclear factor (erythroid derived 2)-like 2
(Nrf2), as key in mediating this phenomenon. Therefore, we
investigated whether increasing Nrf2 expression could
potentially mitigate the decline in NSC regeneration across
the identified critical period. Specifically, recombinant
adeno-associated viral (rAAV2/1) vectors encoding Nrf2
were administered into the SVZs of aging rats, at time-
points either before or after the critical period. Results indi-
cate that animals treated with rAAV2/1-Nrf2, before the
critical middle-age period (at 12 mos), showed greater NSC
proliferation, neurogenesis, and migration, and associated
olfactory discrimination function, compared with animals
receiving control rAAV2/1-eGFP viruses. On the other hand,
Nrf2 overexpression after the critical period (at 21 mos) did
not significantly alter NSC activity at either cellular or beha-
vioral levels. Similarly, enrichment of the hippocampus via
the transplantation of rAAV2/1-Nrf2 overexpressing NSCs
before the critical period alleviated the age-related decline in
SGZ NSC regeneration and improved cognitive function
(pattern separation abilities). Overall, these data highlight
the importance of redox mechanisms in controlling NSC
regeneration and support targeting the Nrf2 pathway as a
potential approach to advantageously modulate NSC activity
with age.
Brain Dysfunction in a Model of Gulf War
Illness Continues into Middle Age with
Elevated Oxidative Stress and Waned
Mitochondrial Activity
L. N. Madhu, S. Attaluri, M. Kodali, L, Melissari,
B. Shuai, R. Upadhya, and A. K. Shetty
Institute for Regenerative Medicine, Department of Molecular
and Cellular Medicine, Texas A&M University College of
Medicine, College Station, TX, USA
Olin E. Teague Veterans’ Medical Center, Central Texas Veterans
Health Care System, Temple, TX, USA
Gulf War Illness (GWI) affects *40% of military personnel
who served in the first Gulf War (GW). Multiple studies
have suggested that concomitant exposure to GW-related
chemicals and stress underlie this illness. The chemicals
include the nerve gas prophylactic drug pyridostigmine bro-
mide (PB), insect repellant DEET, and the insecticide per-
methrin (PM). Our previous studies have suggested that
cognitive and mood impairments in GWI rats were associ-
ated with increased oxidative stress and mitochondrial
hyperactivity in the brain. Here, we examined the progres-
sion of brain dysfunction into middle age in GWI rats. Male
Sprague-Dawley rats were exposed daily to GW-related che-
micals, PB (2 mg/kg), DEET (60 mg/kg) and PM (0.2 mg/
kg), and 15 minutes of restraint stress for 28 days. Five
months later, a series of behavioral tests revealed cognitive
and mood dysfunction in GWI rats. The brain tissue demon-
strated elevated levels of oxidative stress markers in the
cerebral cortex and reduced concentration of antioxidants.
Moreover, the hippocampus displayed increased expression
of genes encoding proteins linked to mitochondrial respira-
tion, with increased levels of mitochondrial complex pro-
teins, which implied the presence of hyperactive
mitochondria. Analyses of GWI rats 12 months after expo-
sure revealed the persistence of cognitive and mood dysfunc-
tion, along with elevated oxidative stress and reduced
antioxidant activity in the cerebral cortex and the hippocam-
pus. However, notably, the mitochondrial activity was
reduced, as evidenced by the decreased expression of genes
encoding proteins related to mitochondrial respiration and
reduced activity of mitochondrial complex I. Thus, cognitive
and mood impairments in GWI continue into middle age
with persistently increased oxidative stress and hypoactive
mitochondria. It appears that mitochondria initially react to
elevated oxidative stress by enhancing their activity. How-
ever, such a compensatory response leads to the production
of higher levels of reactive oxygen species (ROS), which
likely damages the mitochondrial respiratory chain and leads
to hypoactivity.
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A.K.S.).
Transplantation of Mesenchymal Stem
Cells Genetically Engineered to
Overexpress Interleukin-10 Induces
Autophagy, Mitophagy, Molecular
Chaperone Response, and Protected
Neuronal Damage in a Rat Model of
Traumatic Brain Injury
P. Maiti1-6, S. Peruzzaro1,2, N. Kolli1,2, M. Andrews1,2,
A. Al-Gharaibeh1,2, J. Rossignol1,2,7,
and G. L. Dunbar1,2,3,4
1Field Neurosciences Institute of Laboratory for Restorative
Neurology, Central Michigan University, Mt. Pleasant, MI, USA
2Program in Neuroscience, Central Michigan University, Mt.
Pleasant, MI, USA
3Department of Psychology Central Michigan University, Mt.
Pleasant, MI, USA
4Field Neurosciences Institute, St. Mary’s of Michigan, Saginaw,
MI, USA
5Department of Biology, Saginaw Valley State University, Saginaw,
MI, USA
6Brain Research Laboratory, Saginaw Valley State University,
Saginaw, MI, USA
7College of Medicine, Central Michigan University, Mt. Pleasant,
MI, USA
Autophagy plays vital role in neuronal death and survival in
traumatic brain injury (TBI). Transplantation of bone
marrow-derived mesenchymal stem cells (BM-MSCs) has
been shown to increase autophagy and provide neuroprotec-
tion in animal models of neurological diseases by increasing
anti-inflammatory cytokines, such as interleukin-10 (IL-10).
However, due to heterogeneity of MSCs, it is difficult to
measure the levels of IL-10 released by MSCs. We devel-
oped genetically engineered MSCs to overexpress IL-10 in
order to deliver a greater amount of IL-10 to the injured brain
area. The present study investigated the mechanisms of neu-
ronal death and survival, along with autophagy and mito-
phagy markers using a rat model of TBI after
transplantation of BM-MSCs-IL-10. Adult male Sprague-
Dawley rats were divided into four groups: Sham þ Hank’s
balanced salt solution (HBSS), TBI þ HBSS, TBI þ MSC-
green fluorescent protein (GFP)-IL-10 and TBIþMSC-GFP
(n¼9/group). Sham þ HBSS, and TBI þ HBSS received
HBSS, whereas TBI þ MSC-GFP-IL-10 and TBI þ MSC-
GFP were transplanted with MSC-IL-10 or MSC-GFP,
respectively, 36 h after TBI. We investigated the neuronal
changes, using Cresyl violet, Fluoro jade B, and TUNEL
staining. In addition, macroautophagy, mitophagy, and
chaperone-mediated autophagy (CMA) markers, along with
levels of molecular chaperones were analyzed after 3 weeks
of TBI and transplantation. Furthermore, cell survival mar-
kers, synaptic markers, and neuroinflammatory markers
(glial fibrillary acidic protein (GFAP), ionized calcium-
binding adapter molecule-1 (Iba-1)) were also investigated.
We observed a significantly increased number of pyknotic,
degenerated, and TUNEL-positive cells in TBI rats in the
cortex, and in the CA1 and CA3 subfields of the hippocam-
pus in comparison to sham controls. Whereas transplantation
of BM-MSCs-IL-10 significantly reduced cell death in all of
these brain areas, along with increased autophagy, mito-
phagy, CMA markers, and molecular chaperones levels.
Furthermore, cell survival and synaptic markers were
restored and neuroinflammatory markers were decreased
by BM-MSC-IL-10 transplantation. Overall, our data sug-
gest that induction of the autophagy mechanism using BM-
MSC-IL-10 may be used to protect against TBI-induced cell
death.
Association of Hyperacute Blood Pressure
Parameters with Baseline Infarct Volume
and Collateral Status of Patients with
Anterior Circulation Large Vessel
Occlusion undergoing Endovascular
Therapy
P. Moshayedi, S. Desai, C. Hawkes, A. Jadhav,
T. Jovin, and M. Rocha
Department of Neurology, University of Pittsburgh Medical
Center, Pittsburgh, PA, USA
Blood pressure (BP) mean and variability (BPV) have been
previously implicated in clinical outcomes of large vessel
occlusion (LVO) stroke due to unclear mechanisms. Here
we tested whether hyperacute BP parameters are associated
with baseline ischemic core volume and collateral status as
stroke outcomes.
In a single-center retrospective analysis of 94 patients
with middle cerebral artery (MCA) or intracranial internal
carotid artery (ICA) occlusion treated with endovascular
treatment (ET) within 24 h of stroke onset, systolic (SBP),
diastolic (DBP), standard deviation (SD), coefficient of var-
iation (CV), and successive variation (SV) were measured
from door to recanalization time. Associations between BP
parameters with baseline infarct core volume (RAPID soft-
ware) and CTA collateral status (Miteff’s score) were tested
in univariate and multivariate analysis adjusting for age and
National Institutes of Health Stroke Scale (NIHSS).
The mean age of patients was 71+15, median NIHSS
was 17 (IQR, 13–21), 60% were female and the mean
ischemic core volume was 18.6+28.8 ml. The median num-
ber of pre-recanalization BP measurements per patient was
17 (IQR, 13–24). Among 74 patients with collateral assess-
ment 15% had excellent collaterals. Mean SBP (156+23
mmHg) and DBP (79+13 mmHg) were not significantly
correlated with baseline core volume. Mean SBP CV
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(9.7+5.9) had modest correlation with ischemic core vol-
ume (r¼0.215; P¼0.037), which was not statistically signif-
icant in multivariable analysis. Patients with good collaterals
had higher mean SBP (168+24 vs. 154+22; P¼0.039),
DBP (84+9 vs. 77+12; P¼0.025) and minimum SBP
(147+8 vs. 128+3; P¼0.012). Mean SBP (OR 1.04, 95%CI
1.00–1.07; P¼0.047) and minimum SBP (OR 1.05, 95%CI
1.00–1.07; P¼0.01) were independently associated with bet-
ter collaterals. BPV measures were not significantly corre-
lated with collateral status.
Increased BP levels are associated with better baseline
collateral status, but not ischemic core volumes. No signif-
icant association was found between hyperacute BPV and
baseline ischemic core or collateral status. Permissive hyper-
tension may increase collateral capacity in LVO stroke
patients.
T-Cell Phenotype in Murine Osteopontin-
Mediated Aneurysm Healing
K. Motwani1, D. Patel2, D. Wajima3, K. Hosaka1,
B. L. Hoh1
1Department of Neurosurgery, University of Florida, Gainesville,
FL, USA
2College of Medicine, Florida State University, Tallahassee, FL,
USA
3Department of Neurosurgery, Nara Medical University,
Kashihara, Nara, Japan
Cerebral aneurysms (CA), or balloon-like weaknesses in
blood vessels supplying the brain, occur in up to 16 million
individuals or 5% of the US population. Though safer than
open surgery and clipping, treatment by endovascular coil-
ing carries the limitation of up to 44% incomplete treatment.
Our premise is that CA recurrence, often attributed to reca-
nalization, can be mitigated by investigating the immune-
mediated process of endovascular aneurysm healing. Our
previous studies showed that local delivery of osteopontin,
a cytokine expressed by myeloid cells such as macrophages,
improves murine aneurysm healing. We hypothesized that
increased osteopontin improves healing due to downstream
cytokine and cellular mediators. In our established mouse
aneurysm coiling model, we eluted osteopontin into the
aneurysm lumen using a polymer-coated coil to promote
aneurysm ingrowth. Osteopontin-eluting and vehicle coiled
aneurysm tissue lysate were compared by cytokine array for
mechanistic downstream mediators at early timepoints.
Coiled murine and human aneurysms were also sectioned
and immunostained for CD3þ T cells. With osteopontin-
eluting coil placement in our CA model, we observed a
significant increase compared with vehicle control in the
protein expression of CD25 (5.8 fc; p¼0.005) at 1d, ST2/
IL1RL1 (3.5 fc; p¼0.006) at 3d and interleukin-(IL)4, IL5,
and IL9 (>1.5 fc, respectively; p<0.05) at 7d after coil place-
ment. Immunostaining in coiled murine and human aneur-
ysms validated the presence of T cells in aneurysm healing.
With the local delivery of osteopontin into the coiled aneur-
ysm, an increase in CD25, ST2, and type 2 interleukins
indicated a potential role for T lymphocytes in
osteopontin-mediated aneurysm healing. Ongoing cyto-
metric studies will clarify the role of T lymphocytes in this
pathway.
The AAV Alpha-Synuclein Model of
Parkinson’s Disease—Optimization of
Genetic Constructs
J. Mudannayake1, T. Bjo¨rklund2, T. Westerling3,
and F. P. Manfredsson4
1Lund University, Lund, Sweden
2Molecular Neuromodulation, Wallenberg Neuroscieince Center,
Lund, Sweden
3Aiforia, Technologies Oy, Helsinki, Finland
4Department ofTranslational Science and Molecular Medicine,
Michigan State University, Grand Rapids, MI, USA
Animal models based on a-synuclein overexpression that
replicate a range of disease pathology arguably represent a
more clinically relevant alternative to toxins-based Parkin-
son’s disease (PD) models. However, the inability to faith-
fully reproduce the temporal and neurochemical patterns of
pathology and behavior of published work on these models
hinders its wide applicability in the research laboratory. To
generate a replicable, “standardized” adeno-associated virus
(AAV) vector-mediated a-synuclein model, we compara-
tively analyzed commonly used AAV serotypes coupled with
various DNA promoter and post-transcriptional regulatory
elements. We designed various AAV genomes: ssAAV-
CBA-aSyn-WPRE-bGHpA, ssAAV-Syn-aSyn-WPRE-
lateSV40pA, scAAV-CBh-aSyn-WPRE3-enSV40pA,
scAAV-Syn-aSyn-WPRE3-enSV40pA, scAAV-CMV/Syn-
aSyn-WPRE3-enSV40pA, and scAAV-PGK-aSyn-WPRE3-
enSV40p. All constructs were packaged into AAV5, while
scAAV-CBh-aSyn-WPRE3-enSV40pA was also packaged
into AAV2 and 6. Vector titers were determined using digital
droplet PCR in order to ensure future reproducibility. Titer-
matched vectors were unilaterally injected into the rat
substantia nigra and brains were harvested 4 weeks post-
injection. Using tyrosine hydroxylase (TH) immunoreactivity
in conjunction with a neural network/machine learning para-
digm we quantitatively assessed the extent of nigral neurode-
generation. Quantitative near-infrared imaging was performed
to assess transgene expression. We found significant differ-
ences in both a-syn expression and nigral neuron death
between the different AAV constructs. In ongoing experimen-
tation we are assessing the efficacy of selected constructs in
long-term experiments where behavioral deficits are assessed
over time.
This work was supported by the Michael J. Fox
Foundation.
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Regenerative Medicine for Spinal Cord
Injury Using iPS Cells—from Bench to
Bedside
N. Nagoshi1, M. Nakamura1, and H. Okano2
1Department of Orthopaedic Surgery, Keio University, Tokyo,
Japan
2Department of Physiology, Keio University School of Medicine,
Tokyo, Japan
We have reported numerous research results with the aim of
establishing regenerative medicine for spinal cord injury
(SCI). Regarding cell transplantation, we analyzed both the
efficacy and safety using human induced pluripotent stem
cell (iPSC)-derived neural progenitor cells (iPSC-NPCs).
With respect to safety in particular, we focused on g-secre-
tase inhibitor, which inhibits Notch signaling that is neces-
sary for maintaining the undifferentiated status of stem cells.
We administered this drug to determine the tumorigenicity
iPSC-NPCs in vitro. Upon transplantation of iPSC-NPCs
into animal models of SCI, tumor formation was prevented
and motor function was restored. Furthermore, since the
tumorigenicity differs depending on the iPSC lines, we per-
formed genomic / epigenomic analysis which revealed that
expression of tumor suppressor genes and genes for stabiliz-
ing reprogramming was decreased in highly oncogenic cell
lines. To realize safe regenerative medicine, we established a
system for tracking the dynamics of transplanted cells using
PET-CT imaging. By identifying tumorigenesis after trans-
plantation, early intervention such as surgical excision
becomes possible, and the safety of cell transplantation ther-
apy can be guaranteed. Based on the results of these funda-
mental studies, we are steadily preparing for the world’s first
clinical study on SCI using iPSC-NPC transplantation. Clin-
ical iPSCs are supplied from Kyoto University, and we have
already established the method of inducing NPCs with full
evaluation of their efficacy and safety. This clinical research
targets patients at the subacute phase of SCI, and the proto-
col of this study has already been approved by the Certified
Special Committee for Regenerative Medicine. After
approval from the Health Science Council, we plan to start
this project in 2019.
Effects of UBE3A Overexpression in
Sprague Dawley Rats
A. W. Nenninger, M. M. Peters, E. J. Weeber,
and K. R. Nash
Department of Molecular Pharmacology and Physiology,
University of South Florida Morsani College of Medicine,
Tampa, FL, USA
Angelman syndrome (AS) is a disease characterized by
severe intellectual disability, speech and movement prob-
lems, abnormal personality, seizures, and disrupted long-
term potentiation. Interruption in expression or function of
the paternally imprinted UBE3A gene is thought to be the
sole cause of AS. Due to this single gene alteration and lack
of changes in brain structure during development, it is
believed that a gene therapy approach could offer a thera-
peutic treatment. We have previously shown that introduc-
tion of the full-length UBE3A gene using adeno-associated
virus (rAAV) along with stereotactic surgery recovers the
deficits present in AS mouse and rat models. Although gene
therapy is a promising potential treatment, there is some
concern that supraphysiological levels of UBE3A may cause
a separate set of cognitive deficits. Evidence for this comes
from studies of a syndrome closely related to AS known as
chromosome 15q11.2-13.1 duplication syndrome, or
Dup15q. This syndrome results from a duplication of the
region containing the UBE3A gene resulting in increased
levels of the UBE3A protein. Therefore, to investigate the
effects of overexpression of UBE3A, hippocampi of 2-
month-old Sprague Dawley rats were inoculated with
1010(vg) rAAV encoding UBE3A. After aging the rats for
3 months, western blotting was performed on hippocampal
tissue from a subset of animals, which showed a 33%
increase in UBE3A levels in the inoculated group compared
with uninoculated controls with wild-type UBE3A levels.
Behavioral tests including open field, elevated plus maze,
y-maze, novel object recognition, sociability, Morris water
maze, rotarod, fear conditioning, and Digi-gait were per-
formed. No change was found in any behavioral test other
than sociability and some locomotion measures. Electrophy-
siological characterization of hippocampal long-term poten-
tiation was also measured and will be presented. Early data
demonstrate that a gene therapy approach using rAAV-
UBE3A will likely not cause detrimental side effects.
The Role of Interleukin-6 in Murine
Estrogen Deficiency-Associated Cerebral
Aneurysm Rupture
D. Patel, D. Wajima, S. Hourani, C. Jones, K. Motwani,
W. Dodd, H. Z. Fazal, K. Hosaka, and B. L. Hoh
Department of Neurosurgery, University of Florida, Gainesville, FL,
USA
Cerebral aneurysms are balloon-like dilations that occur at
weakened areas of vasculature and affect up to 5% of the
population. Rupture of a cerebral aneurysm results in sub-
arachnoid hemorrhage, which has a mortality rate of approx-
imately 50%. While estrogen deficiency is associated with
cerebral aneurysm rupture, the precise mechanism is
unknown. Healthy post-menopausal women have increased
levels of interleukin-6 (IL-6), a cytokine with pro-
inflammatory activity. We hypothesized that IL-6 promotes
murine estrogen deficiency-associated cerebral aneurysm
rupture. To investigate the clinical relevance of our hypoth-
esis, we analyzed IL-6 expression in human cerebral aneur-
ysm samples compared with superficial temporal artery
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controls. Using our previously established model, we
induced cerebral aneurysms in estrogen-deficient female
C57BL/6 mice. Two different methods of inducing estrogen
deficiency were studied, 4-vinylcyclohexene diepoxide
(VCD) treatment and bilateral ovariectomy (OVE). Mice
were blindly randomized to selective IL-6 inhibition (IL-6
receptor (IL-6 R) neutralizing antibody, n¼25) or control
(isotype-matched IgG, n¼28). Murine cerebral arteries at
the circle of Willis were assessed for aneurysm formation,
rupture, and macrophage infiltration. Results demonstrated
that IL-6 was expressed in human cerebral aneurysm sam-
ples but not in superficial temporal artery controls. In both
methods of inducing estrogen deficiency, selective IL-6 R
inhibition significantly decreased cerebral aneurysm rupture
compared with control treatments (VCD: 31.6% vs. 70.0%,
p¼0.026; OVE: 28.6% vs. 65.2%, p¼0.019). Cerebral aneur-
ysm formation was not significantly affected by IL-6 R inhi-
bition (VCD: 90.4% vs. 95%, p¼1.000; OVE: 84% vs.
82.1%, p¼1.000). Selective IL-6 R inhibition significantly
reduced F4/80þ macrophage infiltration at the circle of
Willis compared with controls (7.6+0.8 vs. 22.9+2.5
stained cells / 100 mm2, p<0.001). Our findings suggest IL-
6 promotes murine estrogen deficiency-associated cerebral
aneurysm rupture via enhanced macrophage infiltration at
the circle of Willis. Similar to our previous studies, the
mechanisms of estrogen deficiency affect cerebral aneurysm
rupture but do not affect aneurysm formation.
Assessing In Vivo Neuronal
Reprogramming by Automated Resonance-
Scanned Confocal Stereology
D. A. Peterson
Center for Stem Cell and Regenerative Medicine, The Chicago
Medical School, Rosalind Franklin University of Medicine and
Science, North Chicago, IL, USA
Direct in vivo reprogramming of non-neuronal cells in the
mature central nervous system (CNS) into phenotypically
correct neurons can be achieved through forced expression
of pioneering transcription factors, such as neurogenin 2
(Ngn2), neurogenic differentiation 1 (NeuroD1), and
achaete-scute family bHLH transcription factor 1 (Ascl1),
that normally act to direct neuronal fate specification during
development. This process produces a variable population of
induced neurons that can be identified through their expres-
sion of reporter genes tied to the induction process and
expression of various neuronal phenotypic markers, requir-
ing detection of multiple fluorescence labels with resolution
by confocal microscopy. Following in vivo gene delivery of
lineage instruction factors, the number of infected cells and
their distribution present some challenges for accurate quan-
titation by design-based stereological sampling. Generally
too many cells are infected to directly count with accuracy
across histological sections, arguing for subsampling of the
population by stereological principles. However, the cell
density varies widely from the site of injection to the most
distant infected cells. This means that sampling frequency
density must be high to reduce estimator variance to an
acceptable level. Traditional acquisition of confocal stacks
is time consuming and inefficient. The recent availability of
resonance scanning confocal microscopes permits the rapid
generation of virtual section data sets. Efficient sampling
design can now follow complete image acquisition of the
histological material. The application of artificial intelli-
gence to detecting cells with different label combinations
within the virtual section data set makes it possible to auto-
mate cell counting if detection criteria can be achieved.
However, cell detection must be combined with stereologi-
cal sampling principles to account for sectioning and other
artifacts and to accommodate fractionated sampling. These
approaches are appropriate for other “rare” cell populations,
such as grafted cells, and could be extended to dense cell
populations if shown to be efficient.
Human Neural Stem Cell Transplantation
in Chronic Spinal Cord Injury
K. M. Piltti1,2,3,4, B. J. Cummings1,2,3,4,
and A. J. Anderson1,2,3,4
1Sue & Bill Gross Stem Cell Research Center, University of
California Irvine, Irvine, CA, USA
2Institute for Memory Impairments & Neurological Disorders,
University of California Irvine, Irvine, CA, USA
3Department of Anatomy & Neurobiology, University of California
Irvine, Irvine, CA, USA
4Department of Physical & Medical Rehabilitation, University of
California Irvine, Irvine, CA, USA
Spinal cord injury (SCI) is a devastating, lifelong neurolo-
gical condition associated with multiple secondary medical
complications, and high economic and social costs. To date,
no established treatment to alleviate the loss of function after
SCI exists. Accordingly, development of new therapeutic
interventions in chronic SCI models is a high priority.
Chronic SCI is an appealing time point for potential therapy,
not only due to the large number of clinical subjects, but also
the reduced probability for spontaneous recovery. In accor-
dance, delayed treatment in clinical trial testing may yield
more reliable safety and efficacy data with lower numbers of
subjects. Our studies have focused on human fetal neural
stem cells (hF-NSC), which represent a multipotent cell pop-
ulation capable of differentiating into neurons, oligodendro-
cytes, or astrocytes, and which can integrate into the central
nervous system (CNS). Critically, hF-NSCs have demon-
strated safety and efficacy after delayed transplantation,
which is critical to the chronic SCI patient population. In
addition, our data suggest that multiple variables such as
transplant location, cell dose, or vertebral level need to be
taken into consideration while developing clinical cell trans-
plantation protocols. However, a critical variable for clinical
success are the intrinsic properties of the target stem cell
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line. Data from multiple studies suggest that biological activ-
ity between individual stem cell lines is not equal and it can
be affected by numerous factors such as in vitro culture
conditions, scale-up, and cell banking. Critically, the current
standard in vitro tests for screening intended clinical cell
lines cannot discriminate stem cell lines with biological
activity / in vivo efficacy from those without. To better
understand the intrinsic differences between the stem cell
lines that show in vivo efficacy from those without, we have
derived a series of new CD133-enriched hF-NSC lines
including cGTP/cGMP-compliant cell lines. In vitro charac-
terization suggests that each new hF-NSC line exhibits stable
growth rate, sustained CD133 selection, multipotency, and
responsiveness to migration cues. However, line to line var-
iations are detectable, highlighting the need to investigate
how this variation is related to in vivo performance, and
whether new approaches to attempt to predict in vivo trauma
modifying activity can be developed.
The Role of eIF5A in TDP-43 Pathology in
FTD; The Tip of the Iceberg?
Z. Quadri1, S. Smeltzer1, F. Zamudio1, A. Loon1,
N. Tirado-Class1, S. Saji1, N. Stewart1, A. Miller1,
Dale Chaput2, D. Lee1, and M-L. Selenica1
1Department of Pharmaceutical Sciences, College of Pharmacy,
University of South Florida, FL, USA
2Proteomics and Mass spectrometry Core Facility, University of
South Florida, Tampa, FL, USA
TAR DNA-binding protein 43 (TDP-43) is a nuclear RNA/
DNA-binding protein that associates with frontotemporal
disorders. The clinical manifestations include motor neuron
degeneration such as that in amyotrophic lateral schlerosis
(ALS) and cognitive decline such as that in frontotemporal
dementia (FTD-TDP-43). FTD remains the second most
common form of early-onset dementia after Alzheimer’s
disease (AD). The hallmark of TDP-43 proteinopathy is
nuclear loss-of-function and accumulation of nuclear and
cytoplasmic TDP-43 inclusions, which acquire toxic gain-
of-function. The unique post-translational modification of
eIF5A, hypusination (eIF5AhypK50), within the hypusination
loop denotes its activation and cytoplasmic localization
where it further interacts with specific RNA binding pro-
teins. eIF5A is implicated in translational elongation and
translation silencing of certain mRNA in stress granules
(SG). Together with our findings we posit that active eIF5A
is positioned as a stress-response protein. Our data show
aberrant increases in enzymes responsible for hypusination
in brain tissue from an AD patient, TDP-43 animal models,
and arsenite-induced stress cellular models, suggesting that
aberrant hypusination underlies the progression of the dis-
ease. Further, we show that arsenite-induced stress induces
interactions between eIF5AhypK50 and cytoplasmic TDP-43.
We also found that eIF5AhypK50 binds TDP-43 and SG
protein TIA-1 during pathology and arsenite-induced stress.
Importantly, we found that pharmacological inhibition of
hypusination and sited-directed mutagenesis induces acety-
lation of eIF5A at lysine 47 (eIF5AacK47), resulting in sig-
nificant reduction of phosphorylated and total TDP-43 in the
cytoplasm and SG. We further confirm that potentiation of
spermidine/spermine N1-acetyltransferase 1 (SSAT1) acet-
ylates eIF5A and reduces the TDP-43 phenotype in cellular
models. Hence, we argue that post-translational modifica-
tions, specifically hypusination vs. acetylation, increases or
subverts TDP-43 pathology, respectively. We predict that
eIF5AhypK50 regulates TDP-43 fate via several potential
mechanisms, including protein–protein binding properties,
increasing TDP-43 cytoplasmic retention or perturbing the
nucleocytoplasmic shuttling of TDP-43 via affecting the
nuclear transport machinery. Here, we discuses the strategies
and approaches that we have employed to dissect the
mechanism of action through which eIF5A affects TDP-43
pathology in FTD disorders and related dementia.
Intermittent Hypercapnia Training to
Improve Respiratory Plasticity Following
Cervical Spinal Cord Injury
M. L. Randelman1,2, L. V. Zholudeva1,2,
T. Bezdudnaya1,2, H. Muralidharan1, L. Qiang1,
M. A. Lane1,2
1Department of Neurobiology and Anatomy, College of Medicine,
Drexel University, Philadelphia, PA, USA
2Spinal Cord Research Center, College of Medicine, Drexel
University, Philadelphia, PA, USA
Cervical spinal cord injury (SCI) frequently leads to severe
respiratory dysfunction due to damage of the spinal phrenic
motor system which controls the diaphragm—the primary
muscle for respiration. While some spontaneous functional
plasticity does occur following cervical SCI, the extent is
limited and diaphragm paresis persists. The goal of this
ongoing research is to test whether a novel activity-based
therapy—daily acute intermittent exposures to hypercap-
nia—can enhance respiratory plasticity and diaphragm
recovery after cervical SCI. We hypothesized that rehabili-
tation with this respiratory-specific activity-based therapy
will stimulate anatomical and functional phrenic plasticity
and improve diaphragm function following a moderate mid-
cervical contusion injury in the adult rat. Anatomical plasti-
city following injury and treatment was investigated using
transynaptic tracing and immunohistochemistry. Pseudora-
bies virus (PRV) was used to retrogradely and transneuron-
ally trace the spinal phrenic circuitry ipsilateral to injury and
assess integration of premotor spinal interneurons with phre-
nic motoneurons. Immunohistochemistry and western blot
analysis were performed to assess changes in serotonin (5-
HT) and brain-derived neurotrophic factor (BDNF) expres-
sion, and axonal growth, rostral and caudal to injury.
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Functional plasticity and respiratory recovery following
dAIHc training was assessed with terminal diaphragm elec-
tromyography (dEMG). Hypercapnia-trained animals
showed a greater density of serotonergic axons within the
spinal cord, yet surprisingly had increased BDNF expression
within the medulla, when compared with untreated and air
control animals. It was also found that 2 weeks of dAIHc
training resulted in a greater recruitment of interneurons into
ipsilateral phrenic circuitry when compared with untreated
and air controls. Diaphragm EMG of the dAIHc-trained ani-
mals resulted in modest improvement of the ipsilateral and
contralateral diaphragm inspiratory amplitude as well as
response to respiratory challenge. These results therefore
suggest that dAIHc is able to promote plasticity within the
phrenic network following cervical SCI.
Gene Expression, Morphological and
Behavioral Changes Associated with a
Mouse Model of Mild Repetitive TBI and
Treatment with Activators of Nrf2 and
PPARg Transcription Factors
W. A. Ratliff1,2, D. Qubty3, C. M. Smith1, T. Michaels1,
C. G. Pick4, and B. A. Citron1,2,3
1Laboratory of Molecular Biology, Research & Development,
Department of Veterans Affairs, Bay Pines, FL and East Orange,
NJ, VA Health Care Systems, USA
2Department of Molecular Medicine, University of South Florida
Morsani College of Medicine, Tampa, FL, USA
3Department of Pharmacology, Physiology, and Medicine, Rutgers
New Jersey Medical School, Newark, NJ, USA
4Department of Anatomy and Anthropology, Sackler School of
Medicine, Tel Aviv University, Tel Aviv, Israel
The incidence of traumatic brain injury (TBI) is estimated at
0.5% per year worldwide, with a much higher frequency
among military personnel and athletes. The majority of TBIs
are mild, but these can result in deleterious cognitive effects
for which there is currently no effective treatment. We have
demonstrated improved outcomes in both in vitro and in vivo
models of brain injury following treatment with tert-
butylhydroquinone (tBHQ), an activator of the
inflammation-responsive transcription factor, nuclear factor
(erythroid-derived 2)-like 2 (Nrf2), and downstream neuro-
protective factors. Additionally, the peroxisome proliferator-
activated receptor-g (PPAR-g) agonist, pioglitazone, has
been shown to have neuroprotective effects in models of
neurodegenerative disease and TBI. To better understand the
underlying mechanisms of injury, we tested mice receiving
closed head injuries once per week for 5 weeks along with
potentially synergistic treatment by tBHQ and pioglitazone.
At acute and chronic timepoints, we evaluated gene expres-
sion, cognitive changes, dendritic changes, and immunohis-
tochemistry for microglial changes. mRNA samples from
the ipsilateral hippocampi 1 day post-injury were evaluated.
Our initial examination (4 groups, n¼6 per group) indicated
that genes displayed a variety of expression patterns. For
example, there was downregulation of secreted phosphopro-
tein 1 (SPP1) and growth hormone (GH) in response to
injury, while treatment resulted in a significant upregulation
of these two factors. Conversely, we saw an increase in
tumor necrosis factor receptor subfamily 25 (TNFRSF25)
with injury and a subsequent decrease with treatment. Two
months post-injury, Golgi staining has revealed significant
changes in dendritic spines within the hippocampi of injured
mice, which is not present with treatment. Behaviorally, we
have shown that object recognition memory is impaired 2
months following injury and that this is ameliorated by treat-
ment. Through these approaches, we hope to better define
inflammatory responsive transcription factor signaling path-
ways and identify factors that could be targeted to produce
neuroprotection and improve outcomes for TBI patients.
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The Effect of hMSCs on Cell Death
Pathways in the Spinal Cord of SOD1G93A
Rats
M. Rˇehorˇova´1,2, I. Vargova´1,2, S. Forostyak1,3,
E. Sykova´1,4, and P. Jendelova´1,2
1Czech Academy of Sciences, Institute of Experimental Medicine,
Prague, Czech Republic
2Second Faculty of Medicine, Charles University, Prague, Czech
Republic
3 Prime Cell Advanced Therapy a.s., Brno, Czech Republic
4Slovak Academy of Science, Institute of Neuroimmunology,
Bratislava, Slovakia
The most recent clinical investigations in patients with
amyotrophic lateral sclerosis (ALS) who underwent bone
marrow mesenchymal stem cell (hMSC) transplantation
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have shown procedural safety and clinical proof of principle
with modest neurological benefits. However, the mechan-
isms responsible for this beneficial effect are not fully under-
stood. In this study, we aimed to investigate the effect of
repeated intrathecal applications of hMSCs in a superoxide
dismutase 1 (SOD1) transgenic rat model of ALS. As a
delivery route we chose lumbar puncture and/or intramuscu-
lar injection. Finally, we studied the effect of the applied
therapies on apoptosis, necroptosis, and autophagy. All the
animals were behaviorally tested (Grip strength test, BBB,
rotarod), and the tissue was analyzed immunohistochemi-
cally, by qPCR and western blot. All symptomatic SOD1
rats treated with hMSCs (into the spinal canal or in combi-
nation with intramuscular injection) had a significantly
increased lifespan, improved motor activity and reduced
number of TUNEL-positive cells. Moreover, a combined
hMSC delivery increased motor neuron survival, maintained
neuromuscular junctions, and substantially reduced the lev-
els of proteins involved in necroptosis (Rip1, MLKL, cl-
casp8), apoptosis (cl-casp 9), and autophagy (beclin 1).
Furthermore, astrogliosis and elevated levels of Connexin
43 were decreased after combined hMSC treatment. The
repeated application of intramuscular injections alone
improved motor activity; however, this improvement was
not supported by changes at the molecular level. We con-
clude that a combination of repeated intrathecal and intra-
muscular hMSC applications protects motor neurons and
neuromuscular junctions mainly through a reduction of the
necroptosis pathway, which is significantly involved in cell
death in rodent SOD1 model of ALS.
Supported by the Center of Reconstruction Neuroscience
– NEURORECON (CZ.02.1.01/0.0/0.0/15_003/0000419)
and LO1309.
Use of Dendrimer Nanoparticles
Encapsulated Curcumin as a Potential
Therapy for Glioblastoma in Mice
J. Rossignol1,2,4, N. M. Munro1,2,4, M. Fana2,4,
B. Srinageshwar1,2,4, C. Malkowski1,2, S. Climie1,2,
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4College of Medicine, Central Michigan University, Mount
Pleasant, MI, USA
5Department of Chemistry & Biochemistry Central Michigan
University, Mount Pleasant, MI, USA
6Field Neurosciences Institute, Saginaw, MI, USA
Glioblastoma (GB), a grade-4 astrocytoma, is an aggressive
form of brain tumor with no cure, having high mortality and
morbidity rates (12 and 15 months after diagnosis). Most of
the anti-cancer drugs do not cross the blood–brain barrier
(BBB). The only treatments for GB are chemotherapy/radio-
therapy, and the average survival is 14.6 months. Previous
studies found increased expression of pro-inflammatory
markers in the GB brain, which results in metastasis and
inflammation. Therefore, decreasing pro-inflammatory
signals and cell proliferation are potential targets for GB.
Curcumin (Cur), a natural phytochemical, is known to have
anti-inflammatory, anti-oxidant, and anti-carcinogenic
properties and can cross the BBB; however, it is not water
soluble, which makes its delivery challenging. Some studies
use lipid formulation of Cur; however, they were found to be
toxic and to increase inflammation in the brain. Therefore,
we used a generation 4 (G4) surface-modified dendrimer
nanoparticle [10% amine surface (positive charge) and
90% hydroxyl surface (neutral charge), known as D] encap-
sulated curcumin (D-ECur) that is water soluble and show
effective release of Cur, having a safety profile in vitro and
in vivo. Moreover, D has a cystamine (Cys) core that can
split to give dendrons facilitating the better release of Cur to
the cells. We used the D-ECur to test the therapeutic effect of
Cur and D in mouse-derived glioblastoma cells lines (Gl261)
and in GB mice. The GB mice were injected with the Gl261
cells to initiate tumor and the D-ECur was injected into the
tumor 1 week later. Our data show that D-ECur (1) are water
soluble; (2) specifically kill GB cells in vitro, sparing the
neurons and glial cells; (3) reduce inflammation in vitro and
in vivo in GB brain; and (4) increase the survival of the GB
mice by*25%. The future aspect involves injecting D-ECur
systemically into the GB mice.
Support for this study was provided by the Neuroscience
program, the College of Medicine, the Field Neurosciences
Institute, and the John G. Kulhavi Professorship in Neu-
roscience at CMU
Investigating the Role of Serotonergic
Hyperinnervation of the Prefrontal Cortex
on Parkinson’s Disease Non-Motor
Symptoms
A. Roux and F. P. Manfredsson
Department of Translational Science and Molecular Medicine,
College of Human Medicine, Michigan State University, Grand
Rapids, MI, USA
Parkinson’s disease (PD) is a common neurodegenerative
disease characterized by the loss of dopaminergic (DA) neu-
rons in the substantia nigra. The gold standard pharmacolo-
gical treatment, levodopa (L-DOPA), can compensate for the
reduced striatal DA. However, over time, the drug loses its
efficacy and >90% of treated patients develop a secondary
set of aberrant motor symptoms called L-DOPA-induced
dyskinesia (LID). We recently demonstrated that LID occurs
as a result of “false DA neurotransmission” from dorsal
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raphe serotonin (5-HT) neurons, which is facilitated by a
significant anatomical reorganization and hyperinnervation
of the raphe-striatal circuitry. Interestingly, L-DOPA is also
associated with cognitive symptoms such as psychosis or
hallucinations, implicating an involvement of additional
brain areas. We hypothesize that akin to the role of 5-HT
hyperinnervation in LID development described in striatum,
that 5-HT innervation in the prefrontal cortex (PFC) is
responsible for these non-motor features of PD. Quantifica-
tion of 5-HT transporter (SERT)-positive projections indeed
demonstrated hyperinnervation in PD versus healthy cases.
Next, we aimed to assess these results in the context of
synaptic activity through 3D reconstruction of SERT projec-
tions together with pre- and post-synaptic markers. Using
Huygens deconvolution and Imaris Software we are per-
forming a volumetric and synaptic analysis of 5-HT projec-
tions. Our data demonstrate that the 5-HT hyperinnervation
is associated with significant “functional” changes such as
different composition of 5-HT synapses. We are determining
whether there is any correlation between any of these histo-
logical measures and reported cognitive symptoms as indi-
cated in the Unified Parkinson’s Disease Rating Scale part 1
(UPDRS1). Our data suggest that the same hyperinnervation
that gives rise to LID is also present in other areas of the PD
brain. It is therefore possible that additional features of PD
are caused by DA release from this circuitry, providing a
novel target for the improved treatment of PD symptoms.
Subcellular Compartmentalization of
Alpha-Synuclein Alters Histone Post-
Translational Modification Patterns and
Chromatin State in SH-SY5Y Cells
I. M. Sandoval1,2, A. Cole-Strauss1, M. Nelson1,
N. Kuhn1, B. F. Daley1, F. P. Manfredsson1,2,
and T. J. Collier1,2
1Department of Translational Science & Molecular Medicine,
College of Human Medicine, Michigan State University, Grand
Rapids, MI, USA
2Hauenstein Neuroscience Center, Mercy Health Saint Mary’s,
Grand Rapids, MI, USA
It is known that the protein alpha-synuclein (aSyn) plays a
crucial role in Parkinson’s disease (PD), but the mechanisms
leading to cell death are still unclear. The main goal of this
project is to determine if localization of aSyn to the nucleus
of dopaminergic (DA) neurons exerts toxicity by altering
histone modification patterns and transcriptional regulation.
To identify epigenetic changes associated with nuclear aSyn
we successfully developed four stable inducible SH-SY5Y
cell lines for controlled expression of wild-type aSyn, aSyn
tagged with a nuclear localization signal (aSyn-NLS) or with
a nuclear export signal (aSyn-NES), and blue fluorescent
protein (BFP) as a control. We found significantly increased
global histone acetylation with cytoplasmic aSyn
expression, and reduced levels with nuclear aSyn expres-
sion. Using ELISA-based assays we have identified several
specific histone modifications that are selectively affected,
including H3K14Ac which has been reported to be altered in
the brain of PD patients. ChIP-Seq experiments are ongoing
to identify genes and pathways affected by these epigenetic
changes. Furthermore, we developed a series of rAAV vec-
tors for in vivo testing: AAVs expressing aSyn, aSyn-NLS,
aSyn-NES, or BFP, as well as GFP tagged with a KASH
domain (nuclear envelope localization domain) for identifi-
cation of nuclei of positively transduced cells. Vectors were
delivered directly into the substantia nigra of young (3
months old) rats by stereotaxic injection and histological
analysis is ongoing to determine whether compartmentaliza-
tion of aSyn (nuclear vs cytoplasmic) has any differential
effects on DA cell death.
Supported by Parkinson’s Disease Foundation (Fellow-
ship PDF-FBS-1634) and Edwin A. Brophy endowment,
Michigan State University
Viral Overexpression of Nurr1 Induces
Severe LID in Resistant Rats and Promotes
Dyskinesia-Like Neuronal Signaling
R. C. Sellnow1, K. Steece-Collier1,2, F. Altwal3,
I. Sandoval1, M. Benskey1, K. Tseng3, A. West4,
and F. P. Manfredsson1,2
1Department of Translational Science and Molecular Medicine,
College of Human Medicine, Michigan State University, Grand
Rapids, MI, USA
2Mercy Health Saint Mary’s, Grand Rapids, MI, USA
3Department of Anatomy and Cell Biology, University of Illinois at
Chicago, Chicago, IL, USA
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Levodopa (L-DOPA) is the gold standard pharmacotherapy
for treating the motor symptoms of Parkinson’s disease
(PD). Unfortunately, chronic treatment with L-DOPA leads
to the inevitable development of L-DOPA-induced dyskine-
sia (LID) in the majority of patients. LID has debilitating and
disruptive motor symptoms comprising chorea, dystonia,
and hyperkinesia. Much research is aimed at better under-
standing LID development. The transcription factor nuclear
receptor related-1 (Nurr1) has been identified by our group,
and others, as being significantly upregulated in the striatum
of dyskinetic rats. Notably, Nurr1 is not normally expressed
in the striatum. In the present study, we sought to character-
ize whether Nurr1 is a causative factor in LID expression. To
examine this we overexpressed Nurr1 (green fluorescent
protein (GFP) as a control) in the parkinsonian striatum of
LID-resistant Lewis or LID-prone Fischer 344 (F344) rats
using rAAV2/5 prior to chronic treatment with L-DOPA.
F344 rats—which are predisposed to developing severe
LID—did not show exacerbated LID in response to Nurr1
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overexpression compared with rAAV-GFP. However, in the
LID-resistant Lewis rats, ectopic overexpression of Nurr1
resulted in the development of severe LID over time.
rAAV-GFP-injected Lewis rats displayed mild LID and no
abnormal induction of striatal Nurr1. This indicates that
Nurr1 is a causative agent capable of inducing LID in oth-
erwise resistant subjects. We further demonstrate that the
ectopic Nurr1 induction associated with LID is dependent
on the activation of striatal D1-type dopamine receptors.
Finally, we also determined that striatal Nurr1 overexpres-
sion increases corticostriatal field potentials and increases
firing activity in dopamine-depleted striatal direct pathway
neurons of L-DOPA-naı¨ve rats, mimicking the activity seen
in dyskinetic rats. Together, this research supports Nurr1 as a
molecular driver of LID that is capable of inducing physio-
logical changes required for these abnormal behaviors to
develop.
Aging Increases Microglia Senescence in
the Midbrain Region: A Risk Factor in
Parkinson’s Disease
F. Shaerzadeh, L. Phan, M. Dacquel, A. Bechtle,
W. Hachmeister, J. Lebowitz, D. Miller, W. Streit,
T. Foster, A. Kumar, and H. Khoshbouei
Department of Neuroscience, University of Florida College of
Medicine and McKnight Brain Institute, JHM Health Science
Center, Gainesville, FL, USA
As highly specialized and dynamic brain-resident macro-
phages, microglia are responsible for maintaining tissue
homeostasis, neuronal support, and protection. There is
growing evidence to support microglial heterogeneity within
the central nervous system, including midbrain regions con-
taining the highest number of dopaminergic neurons in the
brain. Since aging is the major risk factor for neurodegen-
erative diseases, including Parkinson’s disease (PD), we
hypothesized that the ratio of microglia to dopaminergic
neurons, as well as microglial heterogeneity, change with
aging in the substantia nigra pars compacta (SNc) and ven-
tral tegmental area (VTA). To address this hypothesis, we
conducted stereological analyses to measure age-dependent
changes in the numbers of microglia and dopaminergic neu-
rons in the SNc and VTA of 1-, 6-, 9- and 18-month-old
C57BL/J6 male mice. For quantification of the anatomical
features of microglia, we stained coronal sections of the
midbrain with tyrosine hydroxylase (TH) and ionized
calcium-binding adaptor molecule 1 (Iba1), and performed
stereological image analysis. In both brain regions, we found
an increased number of microglia at 18 months, whereas the
number of THþ cells reaches a plateau after 1 month and
does not change thereafter. Quantitative morphometry anal-
yses revealed microglial complexity and the projection area
declined with aging while cell body size increased. Quite
surprisingly, the contact sites between microglia and
dopaminergic neurons in both regions increased in aged
mice, suggesting an age-dependent increase in microglial
support of dopaminergic neurons. In conclusion, increases
in microglial cell number, the ratio of microglia to dopami-
nergic neurons, as well as physical contact sites, suggest
these innate biological mechanisms may compensate for the
age-dependent decline of microglial complexity (senes-
cence) for continued neuronal support in aging. The mor-
phological microglial heterogeneity between adjacent
dopaminergic regions of SNc and VTA found in our studies
may describe the susceptibility of SNc dopaminergic neu-
rons in neurodegenerative diseases such as PD.
In Vivo Delivery of Large Plasmids and
CRISPR-Cas9 to Edit GFP Gene Using
Dendrimer Nanoparticles
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N. M. Munro1,2, B. S. Macdonald1,2, L. Dehart4,
S. Peruzzaro1,2, S. Koneru1,2, S. Baiyasi1,2,
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Dendrimers are 3-dimensional branched nanoparticles hav-
ing applications in the field of medicine. The commonly
used G4 PAMAM dendrimers with 100% amine surface
(G4-NH2) are highly toxic to cells due to their positive
charged surface. Therefore, it is necessary to modify the
dendrimer surface having 10% -NH2 and 90% hydroxyl
group (-OH; G4-90/10), thereby reducing the total number
of positive charges. Our data show that these surface-
modified dendrimers (1) are taken up by neurons and glial
cells in vitro and in vivo; (2) are non-toxic to cells; (3) can
cross the blood–brain barrier (BBB) following systemic
injections; and (4) carry and deliver large plasmids of vari-
ous sizes. We have delivered a *10 kb plasmid with den-
drimer nanoparticles in vitro and in vivo, which is currently
not possible with the viral vectors. In addition, dendrimers
can carry gene-editing plasmids, including CRISPR-Cas9
plasmids. Current strategies to deliver CRISPR-Cas9 rely
on predominately on viral transduction, electroporation, and
hydrodynamic injection. All of these systems have severe
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limitations, largely related to toxicity concerns, minimal
broad efficacy, and plasmid packing size. However, dendri-
mer nanoparticles can carry a single large plasmid having
multiple components to be delivered into a single cell,
thereby enhancing the efficiency of genome editing and the
ability to target multiple tissues. We have shown, as a proof-
of-concept, that dendrimers deliver CRISPR-Cas9 plasmid
(*10 kb), and successfully edit green fluorescent protein
(GFP) into mCherry in vitro and in vivo in GFP mice. Over-
all, we confirm the properties of our dendrimers and show
that we can deliver a large plasmid having multiple compo-
nents of CRISPR-Cas9 system, thereby achieving gene edit-
ing. The future aspect involves delivering various plasmids
and gene-editing tools using dendrimers in vivo.
Support for this study was provided by the Neuroscience
program, the College of Medicine, the Field Neurosciences
Institute, and the John G. Kulhavi Professorship in Neu-
roscience at CMU
The Role of rs6265 BDNF SNP on
Functional Remodeling of the Parkinsonian
Striatum Following Dopamine Neuron
Grafting in CRISPR Knock-in Rats
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Up to 40% of the general population possess a single nucleo-
tide polymorphism rs6265 in the Bdnf gene, which results in
diminished neuronal release of brain-derived neurotrophic
factor (BDNF) and significantly reduces levodopa efficacy
in Parkinson’s disease (PD) patients. BDNF plays a critical
role in nigral and striatal neuron maturation and function.
We hypothesize that dysfunctional BDNF is an unrecog-
nized contributor to the discordant finding of abundant sur-
vival of grafted dopamine (DA) neurons and lack of
behavioral efficacy reported in a subpopulation of PD sub-
jects, and in the development of graft-induced dyskinesias
(GID). To test this hypothesis, we generated a CRISPR
knock-in rat model of the human rs6265 BDNF variant to
evaluate the impact of this risk allele on the function and
synaptic integration of new DA terminals in the parkinsonian
striatum. In this study we compared embryonic DA neuron
graft survival, integration, and behavioral efficacy between
val68 val wild-type (WT, “BDNF normal”) and homozygous
met68met (“BDNF reduced”) parkinsonian rats. Rats were
rendered unilaterally parkinsonian and primed with levo-
dopa (12 mg/kg, M-Fr) to induce stable expression of
levodopa-induced dyskinesias (LID), which was the primary
behavioral endpoint for graft efficacy. Amphetamine-
induced behaviors served as secondary endpoints for graft
efficacy and assessment of GID. Analyses thus far indicate
that contrary to our hypothesis, the Met68Met subjects show
significantly enhanced graft-derived benefit (i.e., ameliora-
tion of LID behavior) compared with WT subjects. How-
ever, consistent with our hypothesis, only Met68Met
subjects exhibited aberrant GID behaviors. Post-mortem
analyses demonstrate that survival of grafted DA neurons
does not differ between the Val68Val and Met68Met sub-
jects; however, the Met68Met subjects have significantly
more robust neurite outgrowth, with enhanced presence of
varicosities. Ongoing post-mortem analyses will include
quantitative assessment of synapse phenotype and degree
of connectivity between grafted dopaminergic neurites and
host neurons.
Supported by Michigan Parkinson Foundation and NIH/
NINDS (R01NS105826).
Role of T Cells in an Alpha-Synuclein Model
of Parkinson’s Disease
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and P. C. Bickford1,3
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Parkinson’s disease (PD) is the second most prevalent move-
ment disorder. It is characterized by up to 70% loss of dopa-
mine (DA)-secreting neurons and accumulation of Lewy
bodies, deposits composed of a-synuclein (a-syn), in the
remaining DA neurons of the substantia nigra pars compacta
(SNpc). Accumulation of a-syn activates microglia, the
immune cells of the central nervous system (CNS). Micro-
glial over-activation causes inflammation and subsequently
leads to neurodegeneration and tissue destruction. Inflamma-
tion caused by the activated microglia and dendritic cells has
been associated with the pathogenesis of PD and several
other neurodegenerative disorders. Recently, apart from
microglia, CD4 and CD8 T cells have been shown to be
recruited to the area of damage where they may either med-
iate neurodegeneration or act in a neuroprotective manner.
The communication pattern between T cells, microglia, and
dendritic cells in PD patients is unknown. Previous work has
shown that injection of human a-syn into the SNpc of the
brain failed to induce neurotoxicity in MHCII (the marker
for activated microglia) deficient mice, suggesting that
T-cell and microglial communication is necessary for the
neurotoxic process. Here, we assessed the role of T cells in
an a-syn model of PD in T-cell-deficient (male athymic
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nude) and T-cell-competent (male heterozygous nude) rats.
Injection of AAV9 expressing human a-syn unilaterally to
the SN of heterozygous nude rats at 3 months of age caused
deficits in a cylinder test for paw bias in comparison to green
fluorescent protein (GFP)-treated controls when the rats
were tested 2 months post-injection. On the other hand, nude
rats injected with a-syn showed no deficit in the cylinder test
when compared with the controls. The percentage of tyrosine
hydroxylase (TH) positive neurons in SNpc was signifi-
cantly lower in a-syn injected T-cell-competent rats when
compared with their T-cell-deficient rat counterparts. These
data suggest that T cells may play a major role in DA neu-
ronal loss and confirm that T-cell communication with
microglia is necessary for a-syn-mediated neurodegenera-
tion in Parkinson’s disease.
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Distinct Neuronal Ensembles within the
Memory Engram Regulate Memory
Discrimination and Generalization
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and Y. Lin1,2
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Memories of previous experiences affect behavioral
responses via balancing discrimination between different
and generalization across similar stimuli. An imbalance
between discrimination and generalization, for example
maladaptive generalization of fear memories, can lead to
anxiety disorders such as posttraumatic stress disorder
(PTSD) and panic disorder. However, the cellular and circuit
mechanisms underlying these two processes are largely
unknown. Here we show that individual contextual fear
memories are represented in the hippocampal dentate gyrus
by multiple functionally distinct neuronal ensembles defined
by the Fos- or Npas4-dependent transcriptional pathways,
and that these ensembles bi-directionally regulate the dis-
crimination–generalization balance. The Fos-dependent
ensemble promotes memory generalization and recruits
excitatory inputs from the medial entorhinal cortex, which
mediates generalization. The Npas4-dependent ensemble
promotes memory discrimination and recruits inhibitory
drive from local cholecystokinin-expressing interneurons,
the activity of which is required for discrimination. Thus
we demonstrate for the first time functional heterogeneity
of the memory engram and uncover novel cellular and circuit
mechanisms regulating the discrimination–generalization
balance. These findings may provide new therapeutic strate-
gies to treat anxiety disorders.
Effect of Chronic Neuroinflammation on
the Clearance of Macromolecules from the
Rat Brain
S. Suresh1,2 and K. Jenrow1,2
1Program in Neuroscience, Central Michigan University, Mount
Pleasant, MI, USA
2Field Neurosciences Institute Laboratory for Restorative
Neuroscience, Central Michigan University, Mount Pleasant, MI,
USA
Two hypotheses have been proposed to explain the removal
of macromolecular waste from the brain extracellular space
(ECS): the classic diffusion model and the recently pro-
posed ‘glymphatic’ model. Both models propose that cere-
brospinal fluid (CSF) facilitates the clearance of these
solutes, albeit by different mechanisms. We hypothesized
that chronic neuroinflammation is sufficient to impair
macromolecular clearance from the brain and may result
in the toxic accumulation of extracellular solutes over time.
To test this, we measured the effect of induced lipopoly-
saccharide (LPS)-induced chronic neuroinflammation on
the clearance kinetics of two fluorescently tagged dextran
tracers from the rat brain using densitometry and spectro-
photometry. We also assessed its effects on the quantity and
distribution of aquaporin 4 (AQP4), glial fibrillary acidic
protein (GFAP), and amyloid-beta (Ab) proteins within the
brain, and behavioral measures of cognitive function. Rela-
tive to controls, neuroinflammation impaired the clearance
of these tracers such that, at corresponding time points,
tracer concentrations were significantly increased in the
brain parenchyma and significantly decreased in blood
serum. Consistent with previous reports, chronic neuroin-
flammation disrupted AQP4 channel distribution on astro-
cytic end-feet processes within the prefrontal cortex and
hippocampus; however, this did not impair the rate of CSF
influx into the parenchyma. Rather, consistent with the
diffusion model, we saw a size-dependent influx of tracer
into the parenchyma in both LPS and control groups.
Chronic neuroinflammation was also associated with ele-
vated Ab in the hippocampus, with punctate Ab deposits
within perivascular space. Behavioral analysis showed
enhanced fear memory and a trend toward context general-
ization in the LPS group, both consistent with chronic
inflammation-induced stress. Our results are generally con-
sistent with the diffusion model of waste clearance from the
brain, and demonstrate that chronic neuroinflammation is
sufficient to impair the elimination of macromolecular
solutes from the brain, which over time may result in the
accumulation of toxic peptides such as Ab, contributing to
cognitive impairment and neuropathology.
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Prolyl Oligopeptidase and its Inhibition on
Alpha-Synuclein Toxicity—A Possibility for
Disease-Modifying Therapy for Parkinson’s
Disease
R. Svarcbahs, U. H. Julku, M. Ja¨ntti, and T. T. Myo¨ha¨nen
Division of Pharmacology and Pharmacotherapy/Drug Research
Program, University of Helsinki, Helsinki, Finland
In Parkinson’s disease (PD), dopaminergic neurons in the
nigrostriatal pathway degenerate, leading to imbalance in
neuronal transmission and clinical symptoms. Although the
causes leading to PD are not completely known, misfolding
and aggregation of alpha-synuclein (aSyn) has been identi-
fied as one of the key players for cellular toxicity in PD.
Aggregated aSyn is the main component for Lewy bodies,
and aSyn oligomers that are formed during the aggregation
process can damage cellular organelles while fibrils can pro-
pagate aSyn toxicity by cell-to-cell transfer. Several factors
can increase aSyn aggregation, and one of them is a serine
protease, prolyl oligopeptidase (PREP). We have shown that
PREP forms a direct protein–protein interaction with aSyn,
leading to increased aSyn dimerization and formation of
soluble aSyn oligomers in vitro and in vivo. Strong coloca-
lization between aSyn and PREP is also seen in post-mortem
PD brain. KYP-2047, a small-molecule PREP inhibitor,
modifies this interaction and reduces aSyn dimerization.
Additionally, PREP inhibition increases macroautophagy
by activating protein phosphatase 2A (PP2A) and decreases
the levels of aSyn oligomers in cells and in vivo. That in turn
ameliorates aSyn toxicity in cell culture models, and our
study showed that post-symptomatic 4-week treatment by
KYP-2047 restored behavioral deficit, decreased aSyn oli-
gomers, and halted damages in dopaminergic neurotransmis-
sion in a mouse PD model based on nigral AAV-aSyn
injection. To assess the impact of PREP and its inhibition
on aSyn propagation, we used aSyn pre-formed fibrils
(PFFs) with Cy3-tag in a neuronal cell culture. After expos-
ing cells to PFFs, 2-day incubation with KYP-2047 signifi-
cantly reduced intracellular PFFs compared with control,
and the same was observed in PREP knock-out cells, sug-
gesting that PREP inhibition or deletion improves PFF pro-
cessing in cells. Therefore, we propose that PREP inhibition
could be a multi-targeting drug therapy having effect on
aSyn aggregation, clearance, and propagation.
LimitedNG2Glial Tropism of Recombinant
Adeno-Associated Viral (rAAV)-Mediated
Gene Delivery for In Vivo Neuronal
Reprogramming
M. Thaqi, E. Reisenbigler, R. Greene, and D. A. Peterson
Center for Stem Cell and Regenerative Medicine, The Chicago
Medical School, Rosalind Franklin University of Medicine and
Science, North Chicago, IL, USA
Direct reprogramming of cell identity from a glial to neuro-
nal phenotype has been demonstrated both in vitro and in
vivo. The induction of phenotypic neurons from glial cell
populations follows forced expression of pioneering tran-
scription factors, such as neurogenin 2 (Ngn2), neuronal
differentiation 1 (NeuroD1), and achaete-scute family bHLH
transcription factor 1 (Ascl1), that are normally expressed
during development to specify neuronal fate. Viral vectors
can be used to deliver reprogramming transcription factors to
glial cells. The efficiency of vector tropism has a major
impact on the feasibility to reprogram a sufficient number
of new neurons to achieve a meaningful functional integra-
tion. NG2 glia, also known as oligodendrocyte progenitor
cells (OPCs), represent one cellular population that could
be an ideal target for neuronal induction for repair. NG2 glia,
understood to represent a reserve cell population to replace
oligodendrocytes, are actively dividing in the mature central
nervous system (CNS), perform no known critical neural
activity, and respond to injury by proliferation and subse-
quent population homeostasis. Previously, we have success-
fully targeted and reprogrammed NG2 glia to neurons in
vitro and in vivo using retroviral vectors to target the
actively proliferating NG2 cell population. rAAV vectors
are an alternative delivery platform frequently used to
achieve efficient and widespread in vivo gene delivery.
However, no systematic assessment of AAV serotype effi-
ciency in targeting NG2 glia has been reported. We delivered
CMV-eGFP constructs into rat cortex and striatum (n¼3
animals per site) using the following AAV serotypes: 1, 2,
4, 5, 6, 6.2, 8, 9, rh10, DJ, PHP.s, PHP.B, PHP.eB. Analysis
of infected cell types, 3 weeks post-injection, revealed most
serotypes were substantially neurotropic with tropism for
astrocytes also observed with AAV5 and AAV8. None of
these serotypes infected NG2 glia to any extent. These data
suggest that targeting reprogramming constructs to NG2 glia
will require designing new and specific AAV serotypes or
utilizing alternatives to AAV.
Sequential Combined Treatment of
Pifithrin-a and Posiphen Enhances
Neurogenesis and Functional Recovery
After Stroke
F. Turcato,1 P. Kim,1 A. Barnett,1 Y. Jin,1 M. Scerba,3
A. Casey,1 W. Selman,1 N. H. Greig,2 and Y. Luo1
1Department of Biochemistry, Genetics and Microbiology,
University of Cincinnati, Cincinnati, OH, USA
2National Institute of Aging, Drug Design & Development Section,
Translational Gerontology Branch, Intramural Research Program,
Baltimore, MD, USA
Although cerebral ischemia can activate endogenous
reparative processes, such as proliferation of endogenous
neural stem cells (NSCs) in the subventricular zone
(SVZ) and subgranular zone (SGZ), the majority of these
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new cells die shortly after injury and do not appropriately
differentiate into neurons, or migrate and functionally
integrate into the brain. The purpose of this study was
to examine a novel strategy for treatment of stroke after
injury by optimizing the survival of ischemia-induced
endogenous NSCs in the SVZ and SGZ. Adult SVZ and
SGZ NSCs were grown as neurospheres in culture
and treated with a p53 inactivator, pifithrin-a (PFT-a),
and an amyloid precursor protein (APP)-lowering drug,
posiphen, and effects on neurosphere number, size, and
neuronal differentiation were evaluated. This combined
sequential treatment approach was then evaluated in mice
challenged with middle cerebral artery occlusion
(MCAo). Locomotor behavior and cognition were evalu-
ated at 4 weeks, and the number of new surviving neurons
was quantified in nestin creERT2-YFP mice. PFT-a and
posiphen enhanced the self-renewal, proliferation rate,
and neuronal differentiation of adult SVZ and SGZ NSCs
in culture. Their sequential combination in mice chal-
lenged with MCAo-induced stroke mitigated locomotor
and cognitive impairments and increased the survival of
SVZ and SGZ NSCs cells. PFT-a and the combined posi-
phenþPFT-a treatment similarly improved locomotion
behavior in stroke-challenged mice. Notably, however,
the combined treatment provided significantly more
potent cognitive function enhancement in stroke mice,
as compared with PFT-a single treatment. Delayed com-
bined sequential treatment with an inhibitor of p53 depen-
dent apoptosis (PFT-a) and APP synthesis (posiphen)
proved able to enhance stroke-induced endogenous neu-
rogenesis and improve the functional recovery in stroke
animals.
Intranasal Administration of Exosomes
from Human iPSC-Derived NSCs Enhances
Neural Stem/Progenitor Cell Proliferation
and Neurogenesis in the Normal Adult
Hippocampus
R. Upadhya, S. Attaluri, M. Pinson, J. Xu, B. Shuai,
and A. K. Shetty
Institute for Regenerative Medicine, Department of Molecular
and Cellular Medicine, Texas A&M Health Science Center
College of Medicine, Temple and College Station, TX, USA
Exosomes are tiny extracellular vesicles secreted by cells.
Exosomes derived from stem cells such as mesenchymal
stem cells (MSCs) and neural stem cells (NSCs) have neu-
roprotective and anti-inflammatory properties. Such exo-
somes may also have neurogenic properties. The use of
stem cell-derived exosomes for enhancing brain function
in normal and disease conditions is attractive as they can
be harvested in large quantities and characterized. Their
small size makes them particularly amenable for administra-
tion to the brain via relatively non-invasive routes, and also
avoids several potential safety hazards linked with cells such
as the risk for tumors. Our previous study has shown that
intranasally administered exosomes can enter virtually all
regions of the forebrain and get incorporated into neurons
and microglia (Castro et al., SFN abstracts, 2017). Here, we
examined the neurogenic property of exosomes generated
from human induced pluripotent stem cell (hiPSC)-derived
NSCs. The conditioned media containing NSC-derived exo-
somes was first processed as described elsewhere (Kim et al.,
PNAS, 2016) and further purified through size exclusion
chromatography. The hNSC-derived exosomes expressed
the exosome marker CD63. We administered these exo-
somes intranasally to adult (5–6 months old) male rats
(*50 billion exosomes/nostril, *100 billion/rat) and exam-
ined NSC behavior and neurogenesis in the subgranular zone
(SGZ) of the hippocampus 14 days after administration.
Measurement of Ki-67 expressing cells in the SGZ revealed
the proliferation of increased numbers of putative NSCs in
animals receiving intranasal (IN) exosomes, in comparison
to animals receiving IN vehicle (p<0.01). Moreover, Ki-67þ
cell clusters in the SGZ of exosome-treated animals were
more substantial, more frequent and comprised a higher
number of cells per cluster (p<0.01). Doublecortin (DCXþ)
immunostaining also revealed increased numbers of DCXþ
clusters containing higher amounts of immature neuroblasts
(p<0.05). Thus, hiPSC-NSC-derived exosomes have neuro-
genic properties. These exosomes may be suitable as biolo-
gics for enhancing hippocampal neurogenesis in conditions
such as aging and disease.
Supported by grants from the Department of Defense
(A.K.S.) and National Institutes of Health (D.J.P and
A.K.S).
Maximum Tolerated Dose of Exosomes
derived from Mesenchymal Stem Cells via
Intra-arterial Dosing in a Rat Stroke Model
M. Watanabe1, A. Khan2, J. M. Hare2,3,
M. Perez-Pinzon1,4, A. P. Raval1,4, E. V Badiavas2,5,
and D. R. Yavagal1,2,4
1Department of Neurology, Leonard M. Miller School of Medicine,
University of Miami, Miami, FL, USA
2Interdisciplinary Stem Cell Institute, Leonard M. Miller School of
Medicine, University of Miami, Miami, FL, USA
3Department of Medicine, Leonard M. Miller School of Medicine,
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5Department of Dermatology and Cutaneous Surgery, Leonard
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Cell therapy is emerging as a promising novel therapy for
ischemic stroke. Exosomes are endosomal-origin small-
membrane vesicles with a size of 40 to 100 nm in diameter,
secreted from many types of cells, for example,
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mesenchymal stem cells (MSCs). Exosome-encapsulated
transfer of miRNAs promotes neurite remodeling and func-
tional recovery of stroke in rats. These data suggest that
MSC-generated exosomes enhance the stroke recovery pro-
cess. There are some publications showing the efficacy of
intravenous exosome administration for stroke, but only one
paper of intra-arterial exosome therapy for a male rat stroke
model without showing the maximum tolerated dose (MTD).
Thus, we are proposing to add intra-arterial exosome deliv-
ery to our current intra-arterial MSCs protocol as a treatment
of stroke for female rats, consistent with STAIR recommen-
dations, with a dose escalation study. Female ovariecto-
mized Sprague-Dawley rats were exposed to middle
cerebral artery occlusion (MCAo) for 90 min. Rats were
treated with IA-exosomes (IAX; 5ug/0.5 mL) or
phosphate-buffered saline (IAPBS) at 1 day (1D) after
MCAo. To test neurological and motor function, the stan-
dardized neurobehavioral test battery and the rotarod test
were performed. The mean duration (in seconds) on the
device was recorded from 3 rotarod measurements. The rats
were tested at 7, 15 and 30 days after MCAo. Rats were
sacrificed at 30 days for infarct volume measurement using
TTC staining. Dose escalation from this dose is actively
being performed in our laboratory. There was no neurologi-
cal worsening or mortality seen in either treatment group.
We observed no difference in infarct volume/rotarod/neuro-
logical scores at 30 days between the 1D IAX group (n¼5)
and the IAPBS group (n¼5, p>0.05). No deterioration was
detected through IAX. We have not met MTD now, but will
show the result of MTD on site.
Micro RNA-29b Can Effectively Inhibit
Alzheimer’s Disease Symptoms and
Maintain Memory
L-W. Wu1,2, S-Z. Lin1,3, H-J. Harn1,3,
and Tzyy-Wen Chiou2
1Buddhist Tzu Chi Medical Fundation, Hualien, Taiwan
2Department of Life Science, National Dong Hwa University,
Hualien, Taiwan
3Hualien Tzu Chi Hospital, Hualien, Taiwan
Alzheimer’s disease (AD) is a degenerative disease of the
brain; its main symptoms include amyloid accumulation and
hyperphosphorylation of the protein. We screened the initial
efficacy of the drug using induced pluripotent stem cells
(iPSCs) that produce symptoms of AD. Among them, Buty-
lidenephthalide (EF-005) can effectively reduce the produc-
tion of amyloid, total protein and phosphorylated protein in
cells at an appropriate concentration. Using miRNA micro-
array biochip assays, we found that when AD-iPSCs were
treated with EF-005, miRNA-29b increased significantly.
The literature also pointed out that increased expression of
PSEN-1 and 2 genes causes amyloid production in the brains
of Alzheimer’s patients. We speculate that miRNA-29b can
bind to the gene sequence fragment of PSEN and inhibit
protein production. This was confirmed using the C6-C99
cell model which can produce amyloid protein. The PSEN
protein was significantly decreased after the addition of EF-
005, and with direct inhibition of miRNA-29b, EF-005 will
not be able to affect the performance of PSEN protein. The
dual luminescence system demonstrated that miRNA-29b
binds to specific gene segments of PSEN and interferes with
gene expression. The gene transfer mouse-3xTg mice with
Alzheimer’s disease were treated with EF-005, and the
changes in amyloid accumulation in the mice brains were
traced through Florbetaben-18F for a long time. After 1 year
of tracking, the oral EF-005 treatment group showed a sig-
nificant reduction in amyloid protein in the brain compared
with the control group. In electrophysiological examination
of the long-term enhancement of the brain, the treatment
group was also superior to the control group. The learning
and memory ability was measured by the water maze, and
the treatment group was also significantly better than the
untreated group. We propose that EF-005 can reduce PSEN
protein by increasing miRNA-29b, thereby reducing the
aggregation of amyloid. Inhibiting excessive accumulation
of amyloid in the brain by promoting miRNA drugs can be a
strategy for preventing and treating AD.
Neural Progenitor Cell Survival and
Expression of Parvalbumin and
Proenkephalin in a Jaundiced Rat Model of
Kernicterus
F-C. Yang1, J. L. Vivian2, S. M. Shapiro3,
and J. A. Stanford1
1Department of Molecular & Integrative Physiology, University of
Kansas Medical Center, Kansas City, KS, USA
2Department of Pathology & Laboratory Medicine, University of
Kansas Medical Center, Kansas City, KS, USA
3Division of Child Neurology, Department of Pediatrics, Children’s
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Neonatal hyperbilirubinemia targets specific brain regions
and can lead to kernicterus. Dystonia in kernicterus is caused
by bilirubin toxicity in primarily GABAergic neurons of the
globus pallidus (GP). Targeting GP with neuronal stem cells
to restore damaged cells is a promising approach to treat
dystonia in kernicterus. Our goal was to investigate long-
term survival and development of transplanted medial gang-
lion eminence (MGE)-like (MGE is the major embryologic
origin of GP neurons) neuronal progenitor cells (NPCs) in
the Gunn rat model of kernicterus. At P10, jaundiced (jj)
Gunn rats were injected with 50 mg or 70 mg/kg of sulfo-
namide, which promotes the transfer of bilirubin into brain
tissue to cause kernicterus. jj rats and non-jaundiced (Nj)
littermates then received WA09 human embryonic stem
cells differentiated into GABAergic MGE-like NPCs into
the GP. Animals were kept for 3 or 7 weeks post
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transplantation. Cyclosporine A (10 mg/kg, sc) was given 1
day before and 3 weeks after surgery; thereafter it was
mixed in drinking water (50 ml/ml). We then conducted
immunohistochemical analyses of brain sections to identify
grafted cells and fibers, and the expression of parvalbumin
(PV) and proenkephalin (PENK), the two most prevalent
neuropeptides in the GP, in the graft. We found that MGE-
like NPCs survived and generated various types of fibers in
jj brains, even after hyperbilirubinemia exacerbation. More
mature graft cells were observed in brains of the 7-week
group than in the 3-week group. PV-ir neurons were more
abundant and mature 7 weeks after grafting than 3 weeks.
Grafted PENK-ir neurons were observed in vivo for the first
time in both the 3- and 7-week groups. Our results reveal
that MGE-like NPCs survive in kernicterus brain and gen-
erate connecting fibers, with a gradually mature appear-
ance, and express major neuropeptides as in the normal
GP. These results support the feasibility of stem cell ther-
apy in kernicterus.
Combining Neural Transplantation with
Therapeutic Intermittent Hypoxia to Treat
the Injured Spinal Cord
L. V. Zholudeva, M. Randelman, R. Dilbarova,
M. Caplan, L. Qiang, I. Fischer, and M. A. Lane
Department of Neurobiology and Anatomy, College of Medicine,
Drexel University, Philadelphia, PA, USA
There is a growing interest in the use of neural progenitor
cells (NPCs) to repair the injured spinal cord. Despite exten-
sive preclinical research, it remains unclear as to how donor
cells develop, differentiate, and integrate with host injured
circuitry, and if integration can be enhanced and/or guided
using noninvasive means such as activity-based therapy.
With a focus on the phrenic circuit and respiratory dysfunc-
tion after cervical spinal cord injury (SCI), the present work
tests the hypothesis that pairing cellular transplantation with
a clinical rehabilitation strategy (daily acute intermittent
hypoxia, dAIH) will enhance neuroplasticity and promote
donor–host connectivity. Cultured NPCs isolated from green
fluorescent protein (GFP) rats yielded neuronal and glial
restricted progenitor cells. While the phenotype of these
progenitors is being determined in ongoing work, excitatory,
inhibitory, and modulatory neuronal precursors are known to
be present. These cells were then transplanted into a clini-
cally relevant cervical (C3/4) contusion injury in adult Spra-
gue Dawley rats, 1 week after injury. Animals received 4
weeks of dAIH (10  5 min exposures to 10% oxygen inter-
mittent with normoxia, 5 days a week), beginning 1 week
post-transplantation. Donor cells survive, differentiate, and
integrate with the host spinal cord as assessed with
transynaptic pseudorabies virus tracing (PRV) and immuno-
histochemistry. Respiratory training resulted in significantly
enhanced donor–host connectivity to ipsi- and contralateral-
to-injury phrenic circuit, compared with untrained transplant
recipients. At least a subset of these newly integrated donor
spinal interneurons are cholinergic. Preliminary data suggest
the underlying mechanism for directing donor cell outgrowth
toward phrenic inter- and motoneurons is in part mediated
via brain-derived neurotrophic factor (BDNF) expression
within the cervical spinal cord. Transplant recipients, with
and without dAIH training, showed greater muscle (dia-
phragm) recovery than vehicle-controls, as measured by ter-
minal electromyography. Interestingly, transplant and dAIH
training recipients demonstrated a greater ability to respond
to hypoxic but not hypercapnic respiratory challenge.
Ongoing experiments are focused on identifying donor
neural phenotypes that become connected to ipsi- and
contralateral-to-injury host circuitry. These experiments
suggest that rehabilitative strategies such as dAIH may be
an effective way for enhancing donor cell outgrowth and
connectivity.
Acute Treatment of a Hypothermic
Compound Attenuates Psychological
Deficits Chronically Developed in Mice with
a Focal Ischemic Stroke
Z. Weiwei1,2, W. Ling1, Y. S. Ping1,2
1Department of Anesthesiology, Emory University School of
Medicine, Atlanta, GA, USA
2Center for Visual and Neurocognitive Rehabilitation, Atlanta
Veterans Affairs Medical Center, Decatur, GA, USA
Stroke is one of the leading causes of disability in the world
and around 30% of patients develop psychological liabilities,
such as post-stroke depression (PSD) and post-stroke anxi-
ety. Basic and translational research on psychological dis-
orders after stroke is limited. A stroke mouse model with a
focal ischemic stroke in the sensorimotor cortex was used in
our study, which showed sensorimotor functional deficits
several days after stroke. The mice underwent spontaneous
recovery in the adhesive removal test and corner test in 2–4
weeks. However, in our study, these animals gradually
developed depressive/anxious behaviors 4 weeks after stroke
and deteriorated until 8 weeks post-surgery in a series of
behavioral examinations, such as the forced swim test, tail
suspension, sucrose preference, and the open field and water
maze tests. Altered neuronal plasticity, suppressed brain-
derived neurotrophic factor (BDNF) and oxytocin signaling,
and disturbed dopamine regulation were detected in the pre-
frontal cortex (PFC) of these stroke animals at 6–8 weeks
post-surgery. Antidepressants are common clinical treat-
ments for PSD; however, their efficacy is far from satisfac-
tory. Emerging evidence has shown that therapeutic
hypothermia is a promising acute protective therapy after
stroke; meanwhile, its effect on post-stroke psychological
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symptoms has rarely been examined. We have developed a
pharmacological hypothermia treatment using neurotensin
receptor 1 (NTR1) agonists and demonstrated brain protec-
tive effects against stroke and traumatic brain injury (TBI).
In the present investigation, we inspected the potential
antagonism of acute post-stroke treatment using the
hypothermic drug HPI363 on chronic psychological disor-
ders in a mouse model of stroke. In stroke mice that received
6 h hypothermic treatment of HPI363 acutely after stroke,
depressive and anxious phenotypes were noticeably attenu-
ated at 6 weeks after stroke, accompanied by restored BDNF
and oxytocin signaling. Our data suggest that an acute
hypothermia treatment induced with PIH363 has a delayed
benefit of attenuating chronically developed post-stroke psy-
chological disorders in mice.
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Extending Cord Blood to Regenerative
Therapies for the Brain
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Studies in children with selective inborn errors of metabo-
lism have shown that cord blood cells, administered intrave-
nously after myeloablative therapy, engraft in the brain.
DUOC-01, a cord blood derived cellular therapy that pro-
motes myelination, is undergoing testing to augment stan-
dard umbilical cord blood treatment in children with
leukodystrophies. These observations led us to hypothesize
that cord blood cells might also have efficacy treating
patients with acquired brain injuries. Clinical studies to date
have been performed to demonstrate safety and efficacy of
intravenous infusions of autologous cord blood in babies
with hypoxic ischemic encephalopathy, young children with
cerebral palsy, congenital hydrocephalus and autism, and
adults with acute ischemic stroke. Further development of
these therapies using allogeneic cord blood products can
provide access to these therapies for all.
Learning Objectives
1. The history and evolution of cord blood banking and
transplantation
2. Quality measures of cord blood units
3. New clinical applications for cord blood therapies
Human iPSC-Derived Corticospinal
Neuronal Grafts To Repair Cervical Spinal
Cord Injury
Vanessa Doulames, James Weimann
and Giles W Plant
Department of Neurosurgery, Stanford University Stanford
CA 94304
Traumatic spinal cord injuries (SCIs) at the cervical-level
sever corticospinal tract axons disrupt the motor circuit
responsible for voluntary movement and pose both an imme-
diate and long-term burden on the patient and health care
system. Whereas the predominant amount of grafts in precli-
nical trials are comprised of undifferentiated and uncharacter-
ized neural progenitor cells, our laboratory has developed a
well-characterized human induced pluripotent stem cell-
derived corticospinal motor neuron (iPSC-CSMN) transplant
relay system to treat cervical SCI. Herein, human iPSCs
underwent a directed differentiation towards a CSMN fate
and were then implanted in immunodeficient nude rats fol-
lowing a C5 unilateral hemisection injury. Cells were pheno-
typically characterized and monitored within the host
corticospinal tract following implantation for growth, migra-
tion, synapse formation, and effect on the injury. Additionally,
anatomical changes were correlated with extent of functional
recovery. At 12-32 weeks post transplantation, iPSC-CSMN
grafts survived, integrated, did not proliferate or migrate,
extend axons long distances, reduce inflammation and lesion
size, allowed for serotonergic and corticospinal tract axon
innervation, and led to significant improvements in forelimb
function. Further investigation is underway to understand
supraspinal innervation of the CSMN grafts and examining
how these fully differentiated iPSC-CSMN grafts respond to
chronic SCIs. Elucidating how to better integrate transplanted
cells into the host neural circuitry to repair and restore func-
tion is a future path of investigation.
Funded by Wings for Life, International Spinal Research
Trust (UK), Eileen Bond Neuroscience Fund, Dennis Chan
Neuroscience fund DoD, and NIH.
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